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This audit was conducted by reviewing two cohorts of patients in terms of pharmaceutical 
care delivered by examining free text electronic records and categorising care issues into a 
proposed reporting system. Qualitative research methods in an action research process were 
used to test the validity and the utility of the reporting system. A template for an electronic 
pharmaceutical care plan that meets defined criteria for service developments including non-
medical prescribing was proposed by the investigators. 
 
Methods 
The investigator identified and gathered documented care plans from samples of patients 
receiving pharmaceutical care during February 2008 to April 2008 using the electronic care 
monitoring system. The context and outcomes of each care plan were identified by obtaining 
additional information from paper case records and through dialogue with the clinical 
pharmacist authors to overcome any gaps in the free text electronic records. An existing 
categorisation system used at the University of Strathclyde was modified to increase the 
robustness and clinical usefulness and a guideline for use of the system was developed.  A 
contents analysis of the care plans was conducted in order to categorise the care issues. 
The inter-rater reliability in the categorisation of the care issues in the survey was 
demonstrated using Cohens kappa analysis. The proposed care plan template was 
evaluated in terms of validity and utility for reporting care plans using an action research 
approach and revised in response to the feedback obtained. The survey findings were also 
reported to the clinical pharmacy team. 
 
Setting 
The survey was sited at the orthopaedic ward at the Ayr Hospital where an electronic 
prescribing system is in use. A clinical pharmacist is at the orthopaedic ward every day from 
Monday to Friday. 
 
Results 
Ideas generated from group meeting with the clinical pharmacist at the Ayr Hospital were 
among others to implement databases and forms that already are used today. The care 
issue section should be more structured and include functions as review date and predefined 
texts.  
 
The 90 patients that were included at orthopaedic ward had totally 270 care issues identified 
compared to the 71 patients at the cardiology ward where totally 377 care issues were 
identified (p<0.0001). The number of care issues per patient categorised as a Check was 
significant higher at the cardiology ward than the orthopaedic ward (3.8 versus 1.1, 
p<0.0001). The subcategory ‘Change in clinical (shared) record of drug history’, which 
includes changes in the patients drug therapy based on errors or omissions in medicines 
prescribed on admission, was relative high on both wards (63 issues on orthopaedic and 37 
on cardiology). For both wards most of the Checks were done during the treatment of the 
patient and therefore categorised as a ‘monitoring’. Similarly were the majority of care issues 
in both of the Change categories found at the ‘verification’ stage in the delivery of the 
patient’s treatment. Few ‘reviews’ were identified among the ‘Changes in drug therapy’ in 
both settings. The inter-rater reliability test for the categorisation found the agreement to be 
highest within the Check and the two Change categories and poorest in the part of the 
system with the Quality Assurance Descriptors ‘Degree of change’. 
 
Conclusion 
A care plan template will make the plan more structured and complete and the 
documentation process more effective and uniform between pharmacists. The categorisation 
system describes the contribution the clinical pharmacist to the patient’s treatment but there 







BD   twice a day (from Latin bis in die) 
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1.1 Clinical pharmacy in the UK 
Hospital pharmacy services have developed and expanded over the last 40 years to 
an extent where the clinical pharmacist has an important role and function in 
individual patients’ care at the hospital ward. The United Kingdom (UK) has the 
largest population of hospital pharmacist in the European Union (EU). A survey from 
2002 shows that around 20% of the pharmacists in the UK are connected to a 
hospital compared to 4-7% for most of the other countries in the EU(1). ‘Clinical 
pharmacy’ has been defined in different ways but can be explained as a discipline 
concerned with making use of pharmaceutical expertise to help maximise drug 
efficacy and minimise drug toxicity in individual patients(2). Surveys of the health of 
the Scottish population shows increasing average life expectancy, although low 
compared with most western European countries(3). Like countries worldwide the 
patients with chronic conditions constitute the largest part of the patient population(4). 
With several patients receiving more complex drugs and drug therapies a practitioner 
with focus on drug treatment monitoring and evaluation is absolutely needed.  
 
The changes in the public health are reflected in the increasing number of spending 
on medicines despite a slightly fall in patients treated in hospitals(5). This has led to a 
range of initiatives to support a safe, effective and economic use of medicines in 
hospitals; national strategy plans for handling the medicines in the National Health 
Service in the UK was published at the start of the twenty-first century. Central in 
both the NHS plan ‘Pharmacy in the Future’ and the Audit Commission’s report ‘A 
Spoonful of Sugar’ is ‘medicines management’ which has been established as a term 
describing processes proposed to optimise the supply and use of medicines in the 
NHS(6,7). In practice this mean changes of the systems around the patient delivering 
pharmaceutical services. Actions to make this a reality are for example the 
introduction of new schemes for use of the patient’s medication, changes in the work 
areas and responsibilities among health care professions and improvement of the 
patient’s journey through the health care system. The national strategy for 
pharmaceutical care in Scotland, ‘The Right Medicine’, published in 2002, 
recommends the hospital service to focus on pharmacists working with patients in the 
wards and clinics(8).  
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1.2 Pharmaceutical care  
Pharmaceutical care is the pharmaceutical contribution to patient care and has been 
defined by Hepler and Strand(9) as: 
 
‘The responsible provision of drug therapy for the purposes of achieving 
definite outcomes that improve a patient’s quality of life’  
 
The essential stages in pharmaceutical care as a model are the assessment of the 
patient’s drug related needs, the development of the care plan and evaluation, 
succeeded by continuous follow-up evaluations to ensure that all drug therapies are 
effective and safe. Altogether this can be described as the patient care process 
which involves the identification of potential and actual drug therapy problems, the 
resolving of the actual drug therapy problems and prevention of potential drug 
therapy problems(9,10).     
 
Pharmaceutical care should be an integrated part in health care(10). The fact that the 
definition of pharmaceutical care does not include any specific health care profession 
emphasise this; it is the care the patient receives that is brought into focus and not 
the type of staff who delivering it. Pharmaceutical care therefore includes every 
health team members contribution to the patient’s medical treatment and not only the 
pharmacist’s(11).  
        
1.2.1 Assessment of the patient on admission  
The assessment of the patient on admission includes taking medication history, 
checking what the patient is prescribed on admission, looking through clinical records 
and talking with the patient, carer or other members of the health care team. 
Establishing an accurate drug history for patients as early on admission to hospital is 
an important part to ensure safe treatment. The accurate drug history can uncover 
reasons for the patient’s illness, for example adverse drug reaction or non-adherence 
to drug therapy. If the errors or omissions are not corrected on admission they will 
form the basis for the therapeutic decisions made for the patient while in hospital and 
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may increase the time spent on discharge correcting these. Drug history taking is a 
skill that needs to be learnt and practised. Pharmacists have shown advantages 
compared to doctors in taking drug history from patients on admission. In a study 
done on a medical admission ward these advantages included fewer errors in the 
history, fewer unintentional discrepancies in medicine prescribed on admission, 
better recording of patient’s use of over the counter and complementary medicines, 
and a more complete recording of allergy status(12). This also supports the 
recommendations from political authorities to have more pharmacists involved in the 
patients’ care at admission and also the implementation of non-medical prescribing to 
reduce medication errors on admission(6,7).   
 
The completeness of the information obtained when assessing the patient is limited 
by the resources available, their reliability and also the skill of the person taking the 
medication history. It is shown that pharmacists are using more sources than doctors 
to obtain the drug history(12). Talking with the patient, if at all possible, is a time 
consuming but important way to confirm the information gathered. It will also give the 
pharmacist an impression of the patient’s relation to and comprehension of their 
medication regimen. In addition this meeting can reveal adverse reactions that the 
patient has due to the treatment. An evaluation of the patient and risk factors related 
to safety and effectiveness of the medicines, a need for closed monitoring or patient 
education is considered (Table 1). If some of the drug-related needs are not met with 
a pharmaceutical product or service as required an already existing or potentially 
developing drug therapy problems is revealed. Such problems are referred to as the 
patient’s ‘pharmaceutical need’ and elements of the pharmaceutical need, which are 
addressed by the pharmacist, can be described in terms of ‘pharmaceutical care 
issue’(2).    
 
 
 Table 1 Drug related need categories(10) 
 
Drug related need 
The medication is appropriate 
The medication is effective 
The medication is safe 
The patient is compliant  
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A desired output is identified for each pharmaceutical care issue. This states the goal 
the pharmacist aims to achieve of the therapy in order to meet the patient’s 
pharmaceutical need. These outputs can be summarised as cure of a disease, 
reduction or elimination of symptoms, arresting or slowing of a disease process and 
preventing a disease or symptoms. Preferably, the goal should include desired 
changes of clinical parameters and/or values of laboratory results specified within a 
timeframe. Target outputs from evidence-based medicine act as treatment 
information and ideal therapeutic goals, but the consideration of the patient as an 
individual should always be kept in mind and the plan individualised accordingly (2,10).       
 
1.2.2 The pharmaceutical care plan 
 
The pharmaceutical care plan functions as a clinical tool to document and structure 
the pharmacist’s contributions to the patient’s care. This documentation has been 
guided in Scotland by a clinical practice guideline from 1996 which recommends the 
recording of actual and potential pharmaceutical care issues within the 
pharmaceutical care plan(2). This includes recording of the pharmacist’s actions with 
the patient, carer and other health team members to address those issues.         
 
Clarity is important when stating or describing an identified pharmaceutical care 
issue. It is essential to describe the patient’s condition, the drug therapy and 
emphasis the specific association between these. In a care plan the pharmaceutical 
care issue is structured into three parts; the desired output of the pharmaceutical 
need, the action(s) planned to achieve the outputs and the actual output. Both the 
action taken and the individuals involved in resolving the pharmaceutical care issue 
should be documented.            
 
To deliver effective pharmaceutical care to patients it is required that the clinical 
pharmacist prioritising the care. The issues resulting highest risk to the patient should 
be resolved or prevented immediately. Subsequently problems that can be resolved 
by the pharmacist and patient directly is prioritised, followed by issues that require 
others, health care profession or relatives, to be included. Although this sounds like a 
matter of course it is important to have it prominently in mind. In a busy clinical 
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setting the prioritising of the care issues is essential to organise the workload to the 
pharmacist.  
1.2.3 Follow up evaluation 
The decision about when to review a patient again to determine the effectiveness 
and safety of the therapy is a clinical decision. Hepler and Strand observed that 
failure to monitor patients’ drug therapy was the most important omission made by 
healthcare professionals(9). All patients receiving drug therapy require some degree 
of monitoring. A monitoring strategy should be capable of measuring progress 
towards the desired outputs and typically are both qualitative (e.g. patients’ reported 
pain) and quantitative (e.g. blood glucose) parameters used(2). When the monitoring 
parameters are known the frequency for monitoring these has to be made. The check 
to see whether the treatment is effective will also ensure that the therapy is not 
creating other problems.   
    
The processes around the patient to achieve the desired output in the 
pharmaceutical treatment can altogether be regarded as a quality assurance system. 
It is emphasised that to meet the desired goal all the parts of this system have to 
improve the level of pharmaceutical care. This demands a fully assessment of the 
patients pharmaceutical needs, clear goals and frequent monitoring. The 
pharmaceutical care plan has the function to document all this initiatives in this 
quality assurance system and it is therefore important to make it complete. An over-
riding objective for the patients’ treatment is continuity in the pharmaceutical care 
he/she receives. The care plan can be used as a document that moves with the 
patient to accompany the patient’s care(11). 
 
 
1.3 Methods for categorisation of pharmaceutical care issues 
As the focus on improving pharmaceutical care delivered to patients is increasing 
through several initiatives from the government, systems designed to describe and 
evaluate the established pharmaceutical services are in demand. To be able to make 
a descriptive tool a standardised language for the activities in pharmaceutical care 
are required and so far limited work with variable methodology in this field has been 
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published(13). Development of structured presentations of the delivery process of 
pharmaceutical care can display in which way the pharmacists contributes to the 
treatment of the patient. It can also form the basis of a description of the 
pharmaceutical care needs within different patient groups or clinical settings and 
information as such can be valuable in strategy decisions in the further development 
of pharmaceutical services.         
     
Through development projects in Scotland a categorisation method to document 
identified pharmaceutical care issues is commenced and tested to a certain 
degree(14). This system consists of three parts which each care issue is assigned 
into:  
 
• Drug therapy problems (Cipolle, Strand) 
• Check or Change category (Strand, McAnaw) 
• Quality Assurance Descriptors (McAnaw, Hudson) 
 
1.3.1 Drug therapy problems 
 
A drug therapy problem is defined by Cipolle and Strand(10) as  
 
‘any undesirable event experienced by a patient which involves, or is 
suspected to involve, drug therapy, and that interferes with achieving the 
desired goals of therapy’. 
 
The drug therapy problem arises when a patient’s drug-related need has not been 
resolved. The identified categories of ‘actual’ and ‘potential’ drug therapy problems 
are associated with the patient’s drug-related needs in focus (Table 2), each referring 
to the undesired output of a drug therapy. The first six categories describe clinical 
problems that the patient experience resulting from the actions of the drug therapy 
while the last category, non-compliance, results from the actions the patient makes 





Table 2 Drug therapy problems as unmet drug-related needs (10) 
 
Drug-related needs Categories of drug therapy problems  
 
1. Unnecessary drug therapy 
 
Medication needs 
2. Needs additional drug therapy 
3. Ineffective drug Effectiveness 
4. Dosage too low 
5. Adverse drug reaction Safety 
6. Dosage too high 
Compliance 7. Non-compliance 
 
 
A paper from 2004 emphasis that although being a recognised classification system 
for drug therapy problems used in published studies, no validation of the usability of 
the system in practice is published(15). In the same paper it is also pointed out that 
this categorisation system does not include potential drug therapy problems and 
therefore can only be employed when the event has already been experienced by the 
patient. As one of the main aims in pharmaceutical care is to prevent potential drug 
therapy problems, a system describing this activity should capture this part of the 
process to be complete.       
 
1.3.2 Check and change 
 
Each pharmaceutical care issue identified by the pharmacist can either be 
categorised as a check or a recommended change. The checks are made at the 
start, during or after a period of a medical treatment for the patient. The types of 
checks are found to closely match the drug therapy problems categories (Table 3). 
When a drug therapy problem is identified it must be clarified whether it is an actual 
or a potential problem. If it is a potential problem it will usually require some form of 
check activity by the pharmacist to confirm, exclude or prevent the problem. If the 
check identifies an actual this can lead to a change recommended or implemented by 
the pharmacist. The changes made are divided by patient behaviour, patient data 
handling and changes in the treatment plan addressed to drug therapy(11). 
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Drug Therapy Problem 
 
addressed by the care issue  









1. Unnecessary drug therapy 
2. Needs additional drug 
therapy 




Patient data handling: 
 
Effectiveness 
 Patient characteristics 
 History (indications, contra-
indications) 
 
3. Ineffective drug 
4. Dosage too low 
Continuity of care 
  Treatment plan changes which 
address: 
Safety 
 Drug choice 
 
5. Adverse drug reaction Dose 
 
6. Dosage too high Route, dose-form 
 
 Dose interval/timing 
Compliance 
 Course duration 
 7. Non-compliance With added precautions/ 
interactions 
  Stop drug pending review 
 
1.3.3 Quality Assurance Descriptors  
 
The use of medicines can be seen to form a treatment cycle (Figure 1).   The 
categorisation system with the Quality Assurance Descriptors is based on the 
description of pharmaceutical care as of what the patient should receive and depicts 
the patients’ medication treatment as a quality system feedback loop. The 
pharmacists’ systematic role identifying care issues is seen as a process within this 
loop(11) and the system is designed to capture monitoring activity of the actual and 
potential drug therapy problems(14). 
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Figure 1 Pharmaceutical care model 
 
 
The check and change categories mentioned above are a part of the processes in 
the quality assurance system the pharmacist contributes to. The checks are situated 
in the quality system feedback loop according to at what time in the patient’s 
treatment course they are done. A check made at the design stage of a treatment to 
assure the appropriateness of the medication in the proposed treatment plan, is 
known as a ‘verification’. A check for safety and effectiveness as the treatment is 
delivered is a ‘monitoring’, while a check to evaluate if the treatment produces a 
positive outcome is a ‘confirmation’ (Figure 1). 
 
This system has also three quality assurance descriptors assigned the changes 
recommended in the patient medication loop. The starting point for these descriptors 
is the agreed treatment plan for the patient; a recommended change that 
individualises the pharmaceutical care within the agreed treatment plan is defined as 
an ‘adjustment’. A change recommended as a result of a review by the health care 
team of the initial treatment plan is described as ‘prompting a review’ while the third 
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descriptor, ‘modification’, is defined as any other recommended change than an 
‘adjustment’ or ‘prompting a review’  (Figure 1)(11). An ‘adjustment’ and modification’ 
can both be made at the start of and as the patient undergoes the treatment, while 
‘prompting a review’ is done after a period of treatment course.     
       
1.4 Electronic prescribing in the UK 
Electronic prescribing (known in the United States as computerised physician order 
entry) has been identified as a core service for all Trusts in the National Health 
Service through the national UK programme for information technology(17). The 
strategy plan sat out that all trusts to have installed electronic patient record systems 
including the reporting of results and prescribing within 2005. No recent surveys 
investigating the extent of implementation of electronic prescribing systems in UK 
hospitals have been found, but a survey from 2000 indicated that there were only 2% 
of hospitals with full electronic prescribing facilities(18). Both issues related to change 
of working practice and the late evolution of software are factors that have been 
mentioned as possible explanations for the poor implementation of the electronic 
prescribing system(19).  
 
Most of the research within this field originates from US hospitals where electronic 
prescribing systems are more widely implemented. These results may not be 
applicable to UK settings because of the difference in systems of medication 
prescribing and supply. Studies from UK hospitals have observed benefits of using 
electronic prescribing including a reduction in rate of medication related errors, 
improvement in legibility and comprehensive audit trail of prescribing decisions 
made. These few studies have their limitations in that they are hard to generalise 
since their one-ward studies, they give little information about methods and 
definitions used and more quantitative data is demanded(20). 
 
A study recently published showed that implementing an electronic prescribing 
system reduced both the number of prescribing errors and the number and types of 
pharmacists’ clinical recommendation(21). Despite a reduction in the number of 
recommendations made by the pharmacist the time spent on the ward did not 
decrease with electronic prescribing. This can be explained by both that not all 
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recommendations were documented but can also be due to better availability to the 
patient’s medication charts(22). An important aspect of these systems is the 
identification of new error types that are specific to electronic prescribing. These 
errors are often involved in the selection of ‘predefined orders’ (PDOs), a function 
which makes it more easily to capture complete data when prescribing by selecting a 
complete medication order in one process. This can nevertheless lead to errors 
because of incorrect or inappropriate selection of PDOs. Some of these errors can be 
solved by improving the software, but it is just as important that the staff using the 
systems is aware of these types of errors to be able to detect and minimise them(21).      
 
1.5 The new services introduced 
As the hospital pharmaceutical services have evolved over the past decades to 
become an integrated and established part of hospital healthcare attention has been 
brought to the re-design of these services, with the primary objective to improve 
patient focus by making the systems more efficient, timely and safe(6-8). The 
continuity of the patients’ medication supply while moving between care settings is 
also highlighted as a problem intended to be solved by re-designing the pharmacy 
services(23). Three of the arrangements outlined for implementation in the National 
Health Service hospitals are one-stop dispensing, use of patients’ own drugs and 
self-administration schemes. In a survey from 2002, including 82 dispensary 
managers from different trusts in the UK, 77% had programmes that used patients’ 
own drugs, while 48% had implemented the self-administration scheme(24). Due to a 
small sample size a generalisation of these results referred to hospitals in the UK is 
uncertain and there is a need for newer information. A fieldwork done by Audit 
Scotland in 2003/04 shows limited implementation of these re-design schemes in 
most of the health boards in Scotland(5). By introducing supplementary and 
independent prescribing by pharmacists national authorities also encourage to 
improve the co-operation between medical and pharmacist practitioners and to better 
utilise pharmacists’ expertise for the benefit of patients(8). 
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1.5.1 Re-use of patients’ own drugs  
Patients’ own drugs (PODs) (also known as patients’ own medications) is a term 
used for the medications that patients have obtained in the community setting and 
bring to the hospital when admitted. On admission the medicines are assessed, 
usually by pharmacy staff, and if the quality is deemed satisfactory, and the medicine 
is still required, the patients’ own medicines are used during the inpatient stay and on 
discharge.  
 
The criteria for deciding PODs suitability vary between hospitals but should ensure 
that the medicines show sufficient quality regarding: intact and clearly identifiable 
container, proper labelling according to patient name, strength, dose and frequency 
of the medicine, storage and expire date. Not all hospitals consider controlled drugs 
and medicines in compliance aids justifiable to use while the patient is on the ward 
due to the potential problems of tablet identification and continuation of supply on 
discharge. Dependent on the strictness in criteria, the proportion of PODs found 
suitable to use in hospital varies from place to place and studies show a suitability of 
PODs brought in vary from 73-77%(25).  
 
Another consequence introducing a re-use of the patients’ own drugs scheme is that 
the medicines are stored in the patients’ bed-side locker from which nursing staff 
administered them. Conflicting data on whether drug administration from individual 
patients’ cabinets is associated with reduction in drug administration errors by nurses 
when compared with use of a drug trolley. In a study from two wards the introduction 
of administration of medication from bedside medicine cabinets did not affect the 
overall proportion of medication administration error defined as any dose omitted or 
deviated from the written medication order(26). Another study used the number of 
interruptions that nurses experienced during the administration process as a 
measure of safety. A reduction in interruptions by 64% after implementation of the 
PODs system was identified (27). Although these results can not be compared directly 
they show different aspects of the changes in drug delivery processes related to the 
use of PODs.    
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1.5.2 One-stop dispensing 
One-stop dispensing, also referred to as ‘dispensing for discharge’, refers to the 
practice of combining inpatient and discharge medicines into a single supply on 
admission, already labelled with administration instructions for the patient to take 
away on discharge. Such schemes generally involve the use of PODs, with supply of 
new medicines from the pharmacy stock as required, to complete the patients’ 
discharge prescription. The patients are typically given a 28-days supply of their 
medicines on discharge, with exclusions where indicated e.g. controlled drugs, 
antibiotics, laxatives are typically supplied for a shorter time of period.  
 
1.5.3 Self-administration of medication  
A patient’s ability to self-medicate while in hospital is preferably assessed by nurses, 
because they spend more time with the patient, but a pharmacist may also be 
involved where pharmaceutical advice is needed. A difficulty with this scheme is that 
the patients on an average do not stay in hospital long enough to be assessed 
properly. Therefore this is primarily implemented on long-stay wards or for patients 
that are not acutely unwell, e.g. rheumatology ward. The majority of patients have an 
unsatisfactory understanding of their medication, despite education and information 
from the health carer, to be able to self-administrate them in hospital. Still the 
independent administration of medicines can be an effective aid for improving 
adherence to medication regimens for selected patient populations, as those with 
chronic conditions(28).   
 
1.5.4 Advantages and disadvantages of the medicines re-design services 
 
The schemes with re-use of PODs and one-stop-dispensing ensure continuation of 
therapy during and after the patients’ hospitalisation in several ways. In a systematic 
review, where 14 of the 19 primary studies included were from hospital settings in the 
UK, the accuracy in the patients’ medication history taken on admission was 
improved when using PODs(25). One study shows that checking PODs is special 
useful in identifying errors and omissions when taking drug history on admission(29). 
Furthermore the risk to patients from having unsuitable medicines at home is 
reduced with the scheme as these will be destroyed and patients will not have 
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duplicate supplies of medicine dispensed by the pharmacy and their own medicines 
at home. Although not easily measured these schemes give health care providers 
additional opportunities for patient counselling and direct patient care. 
 
The one-stop dispensing scheme should result in a quicker discharge, which is an 
advantage both for the patient and the hospital bed management, and the time spent 
on dispensing is reduced since this is only done once. There are still ward settings 
where this scheme may not be suitable.  Because the patients’ medication most likely 
is changed during the stay or the patients’ stay is over a longer time of period and 
therefore the medication is likely to need re-dispensing before discharge, resulting in 
increased workload for pharmacy staff(30). Giving the supply of medicines on 
discharge ensures continuity of therapy after discharge in the way that the patients’ 
general practitioner, through the discharge letter, is aware of changes in the patients’ 
drug therapy during the stay in hospital before the patient attends the General 
Practitioner surgery in need for new prescriptions. 
 
The main evidence for hospitals implementing this scheme is saving in drug costs by 
decreased wastage of PODs, either by preventing loss or avoiding destruction of the 
medicines. It is an effective way in saving costs for the National Health Service and 
also a necessity when it is estimated that medicines worth £15 million may be wasted 
each year in Scotland(8). A disadvantage with the redesign of the service at the ward 
is the additional workload, as a result of the assessment of the PODs, which means 
increased training and staff costs. An initial cost of lockable bedside cabinets must 
also be taken into consideration when starting the implementing, but the financial 
support is eased with the inclusion of these schemes in government strategy 
documents. A comprehensive economic analysis which also includes associated 
costs for additional personnel involved in delivering the PODs is needed(25). 
 
1.5.5 Non-medical prescribing in the UK 
There are two models of pharmacist prescribing in the UK: pharmacist 
supplementary prescribing and pharmacist independent prescribing introduced in 
2003 and 2006, respectively. These changes in roles and responsibility in the health 
care setting comes as a result of a government policy with the desire to make the 
prescribing, supply and administration of the medicines more efficient by making a 
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greater use of the clinical skills of health care professions as nurses and 
pharmacists(6). 
 
In supplementary prescribing a voluntary partnership between the responsible 
independent prescriber (a doctor or a dentist), the supplementary prescriber and the 
patient is established and a clinical management plan for the patients’ disease 
agreed on. In practice the medical practitioner establishes the diagnoses and initiates 
the patients’ treatment while the pharmacist monitors the patient and prescribes 
further supplies of medication only within the limitation of the clinical management 
plan and for the diagnosis included. An independent prescribing pharmacist will, 
unlike a supplementary prescribing pharmacist, be able to prescribe any medicine 
within all drug classes and for any condition, except for Controlled Drugs and 
unlicensed medicines. This increased degree of autonomy gives the pharmacist the 
opportunity to optimise the treatment by responding to the signs and symptoms of an 
additional clinical problem based on an overall assessment of the patient’s treatment.   
 
Pharmacists become licensed to be a supplementary prescriber after completing a 
training course given at both of the Schools of Pharmacy in Scotland. The first course 
for independent prescribing pharmacists is held in 2008. A survey from 2005 
exploring the experience of supplementary prescribing in the UK found that 48.6% of 
401 respondents (82% response rate)  self-reported practising supplementary 
prescribing(31). The pharmacists from the same survey brought up better patient 
management and job satisfaction as benefits of implementing supplementary 
prescribing. On the other hand barriers as restrictive clinical management plans and 
poor recognition of pharmacy role by other health professionals were mentioned. The 
former problem can be solved by the ongoing introduction of independent 
prescribing. Any changes in traditional roles in health care are difficult to introduce, 
but the new role with supplementary and gradually independently prescribing 
pharmacist is not intended to replace any other health care provider. Most of the 
already implemented supplementary prescribing pharmacists are found in special 
clinical areas as TPN/clinical nutrition, oncology-haematology and heart failure or 
cardiology(32) and a contribution of specialised management of patients with identified 
clinical conditions can be one of the main roles for the independently prescribing 
pharmacist.     
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1.6  Clinical audit   
The concept clinical audit has evolved since it was first introduced in the National 
Health Service in the early nineties. Initially medical audit, it soon evolved to 
encompass all aspects of patient care, and with the involvement of other health care 
professionals it became clinical audit(33). Clinical audit is defined as  
 
‘a quality improvement process that seeks to improve patient care and 
outcomes through systematic review of care against explicit criteria and the 
implementation of change’(34).   
 
Clinical audit is a key clinical governance process which enables a healthcare 
organisation to identify, introduce and monitor best clinical practice(33). Clinical 
governance is a framework outset in 1998 and relates to all people who are involved 
in the treatment and care of patients within the National Health Service organisations 
to continuously improve and safeguard the quality of care being provided to patients.   
 
NHS Quality Improvement Scotland is a special health board responsible for assuring 
that there is a clinical audit program within local trusts, and that this reflects national 
audit priorities. A programme of prioritised clinical audits within each health board is 
approved and followed up by the special health board. Over the last few years a 
substantial amount of clinical audit work has been undertaken within NHS Scotland 
on a wide variety of topics funded both centrally and through local clinical 
governance departments(35). A new strategy for future direction of National Clinical 
Audit in Scotland is currently developed. 
 
1.6.1  The process of a clinical audit  
 
A clinical audit can be described as a continuous cycle or spiral that involves 
observing practices, setting standards, comparing practice with standards, 
implementing improvements and observing new practice to ensure that the 
improvement is maintained. As this systematic process continues each cycle aspires 
to a higher level of quality ensuring that the best possible service to patients is 
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offered and the risk of errors minimised. A clinical audit should be viewed as an 
integral part of practice and as a part of quality assurance. 
 
Each cycle in a clinical audit includes the following stages: 
• preparing for audit 
• selecting criteria 
• measuring performance 
• making improvements 
• sustaining improvements 
 
The process of audit involves multiple methods, such as document searching and 
analysis. It can also include collection of information by focus groups or by 
questionnaire. Both qualitative and quantitative methods for collecting descriptive 
data about process and structure can be used for a clinical audit(36).   
 
1.7 Action research 
Action research has the purpose to influence or change some aspect of whatever is 
the focus of the research. The roots of action research as a method lie in the first half 
of the twentieth century. Kurt Lewin (1890–1947), a social psychologist, is often 
credited with coining the term, connecting it to the way of learning about 
organisations through trying to change them(37). The method has since that been 
described and influenced by many authors but some fundamental criteria can be 
found which together distinguish the action research methods from other research 
methods.  
 
A definition of action research, based on a review on the literature found, try to 
embrace the distinguishing features from previous definitions: 
 
‘Action research is a period of inquiry, which describes, interprets and explains 
social situations while executing a change intervention aimed at improvement 
and involvement. It is problem focused, context-specific and future-oriented. 
Action research is a group activity with an explicit critical value basis and is 
founded on a partnership between action researchers and participants, all of 
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whom are involved in the change process. The participatory process is 
educative and empowering, involving a dynamic approach in which problem 
identification, planning, action and evaluation are interlinked. Knowledge may 
be advanced through reflection and research, and qualitative and quantitative 
research methods may be employed to collect data. Different types of 
knowledge may be produced by action research, including practical and 
propositional. Theory may be generated and refined, and its general 
application explored through the cycles of the action research process’ (38). 
 
Two criteria found as key components of the framework in all action research are the 
research partnership and the cyclic process. In the theory about action research the 
process is widely adopted as a cycle or spiral containing stages of problem 
identification with reflection on practice, planning, action taken with a succeeding 
evaluation. The last phase may lead to identification of new problems and so the 
cycle repeat. In this way the research takes shape as it is being performed(38,39). This 
stages aid to understand the process better although it is not always attained; if e.g. 
the project with action research is used to explore the acceptability and feasibility of 
an intervention and finds it is not acceptable to carry through; the change in practice 
is not implemented. By giving the term intervention a broader meaning in the action 
research process this can equally refer to changes in the participants understanding, 
beliefs, values and behaviour. 
 
Action research, unlike other forms of research, includes those subjects who are 
being studied, whether they are practitioners or clients, as participant ‘co-
researchers’. This implies participation in both the development of ideas about what 
to study, the carrying-out and the interpreting of the results. The collaboration 
generates more easily interest and expands the ownership for the research to more 
than the researcher alone. As action research requires the participants to share 
experience, knowledge and ideas, with a view to researching and evaluating them, 
the research method also has an educative function. Including those who are being 
studied has the disadvantage that the phases of the research process are more time 
consuming than in other methods. To avoid conflicts arising among participants  
management of the group is an important factor to succeed using the action research 
method(37,38).    
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In mainstream research, practice developments are secondary to the research. This 
scenario is reversed in action research, in which the emphasis is on practice or 
behaviour, with research being a tool to bring about and support change(38). Action 
research uses multiple research methods, most of which are qualitative, although 
some quantitative surveys may also form a part of the process. Other methods as 
focus group and in-depth interview are often used to give the participants an 
opportunity to be a part of the decision-making. 
 
A scoping study from Scottish Government Health Directorates describes the theory 
practice gap in healthcare. It is emphasised that “evidence about good practice is 
often failing to become good practice”. Due to the lack of implementation of research 
based practice the attention on alternate methodologies such as action research has 
been focused on. Action research has been used to a limited extent as research 
method in health care studies in Scotland and the authors encourage the National 
Health Service organisations to collaborate with academics with interest for the 
action research method to develop models and framework using this as an 
improvement method(40).  
 
1.8  Focus groups 
A focus group is a type of group interview technique used for qualitative data 
collection. The method makes use of the interaction with the participants and the 
group leader to stimulate discussion, gain insights and generating ideas in order to 
pursue a topic in greater depth. Thus the focus group does not only examine what 
people think but how they think and why they think that way(41).  
 
The group typically contains between six and twelve participants with the investigator 
as a group leader, referred to as a moderator or a facilitator, who uses a list of topics 
or questions to stimulate and guide the discussion. The moderator needs to be 
skilled at creating a relaxed atmosphere, leading group discussion and handling 
conflicts, as well as drawing out passive participants. The discussion lasts about one 
hour and is generally audio-recorded. The advantages of having a second researcher 
involved in the running of the group are that he or she provides coverage of both the 
substantive area of interest and focus group experience. It is also a good practise to 
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have written observational notes made by this second person, even though the 
session is recorded. 
 
Focus groups are particularly appropriate as qualitative research tools when the 
interviewer has a series of open ended questions and wishes to encourage research 
participants to explore the issues of importance to them, in their own vocabulary, 
generating their own questions and pursuing their own priorities. In unstructured 
approaches like this questions are typically divided into main questions which guide 
the interview, probes and follow-up questions(36). Since the method has the potential 
to raise consciousness and empower participants it is often used in action research 
where the investigator aspires to make the participants feel that they are an active 
part of the research process(41,42). 
 
1.8.1 Area of application of focus group  
Although the focus group method can be used as the primary data collection method 
in a study, it has frequently been combined with other research methods where it 
generally employs as a research tool at different stages within larger exploratory and 
descriptive studies. Other uses include the focus group as a precursor to the 
development of a more structured instrument to ensure content validity, or the 
reverse sequence is also possible, for example using focus groups to amplify and 
understand the findings from a survey (37,42). As the value of qualitative research has 
been more widely acknowledged, there has been increasing interest in the 
application of focus groups in pharmacy practice and health services research. In 
common with qualitative studies, focus groups are employed to research views and 
experiences, and identify their concerns and priorities which may explain behaviour 
patterns.  
 
1.8.2 Disadvantages of focus groups 
The analysis and interpretation of the data gathered in focus groups is a time-
consuming and difficult stage of the method. Although the focus group in itself can be 
set up relatively quickly, they are not easy to conduct well and the skills and 
attributes of the moderator and the manner of data recording will exert a powerful 
influence on the quality of the data collected(36,37). In a qualitative method like this the 
 35 
results should only be found valid if data are an accurate reflection of the 
perspectives of the participants. The group dynamics or power hierarchies that affect 
who speaks and what they say can imply problematic methodological issues. 
Generation of only "surface" information on individual respondents is a disadvantage 
of the interview method since it is difficult or impossible to follow up views of 
individuals as in in-depth interviews. Generalisation from focus group data is 
problematic due to the sample size and to which extent the sample is representative 
of the population. Often the findings from focus groups are not intended to be 
generalised for a wider population, but rather designed as preliminary explorations to 







1.8.3 Electronic prescribing in the Ayr Hospital  
 
An electronic prescribing system has been established in the Ayr Hospital since 1997 
as one of the National Health Service UK pilot sites and as the only national pilot site 
in Scotland. The existing electronic prescribing system used at the Ayr Hospital, 
Electronic Prescribing and Medicines Administration (EPMA) system provided by 
JAC Computer Services Ltd, is linked to the pharmacy stock control system and the 
hospital patient administration system and provides online prescribing support and 
generates electronic discharge prescriptions. An electronic health record system is 
not yet implemented and so the patient medical notes are still paper based.  
 
In the electronic prescribing system the prescriber can choose from a list of the 
medicines included in the local formulary of the hospital, all with predefined orders for 
dose frequency. The medicines prescribed for the patient are displayed in sections 
based on whether it is given as regular medication, as required medication, 
continuous or intermittent infusion (see example appendix 1). All items prescribed for 
the patient can be modified, discontinued, suspended and resumed during the 
treatment. The system also supports once-only orders and treatment courses where 
the time for stop can be automatic dependent on number of administrations or days. 
In addition orders can be prescribed with optional route of administration (e.g. 
cyclizine tablets and intra muscular injection), giving the nursing staff the opportunity 
to choose the clinically most appropriate product for the patient when administrating 
the medicines. When medicines are administered the staff nurse moves from patient 
to patient with a computer attached to a trolley. The computer displays the required 
medication at each administration period and an electronic signature telling when the 
drug was given and by whom.  
 
1.8.4 The clinical pharmacists actions on the electronic prescribing system 
 
The electronic prescribing system can be accessed from anywhere in the trust that 
has a networked computer. The pharmacists at the Ayr Hospital have their own 
laptop personal computers which they can bring with them on the ward if necessary. 
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At Ayr delivery of hospital inpatient pharmaceutical care and transfer of care at 
discharge has been developed within the national framework for clinical pharmacy for 
hospital pharmacy that has been in place in Scotland since 1996(2). On the electronic 
prescribing system in use the pharmacists make on line pharmaceutical care plans. 
‘Clinical notes’ is a function that can be added to the patient or the drugs prescribed 
with the purpose to give messages to the health care personnel involved in the 
medication of the patient. This note file makes the basis for the care plan (Appendix 
1).  
 
Any prescription made by a doctor is treated as unverified. The clinical pharmacist 
verification is a function in the electronic prescribing system for pharmacists to 
clinically check a prescription. In the verification process the pharmacist also can add 
information such as whether the patient was admitted on the medicine or have their 
own supply to be recorded. A drawback with this version of the system is that if the 
verification of a prescription is done in error can not be changed back/’unverified’. An 
other function is used by the clinical pharmacists if an order prescribed is found 
inappropriate and he/she want to speak to the responsible doctor. The pharmacist 
awaits a verification of the drug, withheld the order and clarifies the problem with the 
prescriber. An order not verified or withheld by the pharmacist does clearly display 
the pharmacist’s view of the order to all the users of the system, but the functions do 
not affect the possibility to administrate the drug. To ensure that the patient’s are 
prescribed the correct drug treatment as required the pharmacist can also transcribe 
patient’s medicines into the electronic prescribing system.  
 
The Ayr Hospital provides an environment in which a documented, targeted, 
comprehensive, clinical pharmacy service has become established to a point at 
which the pharmacy team has the need to review its care planning documentation 
and report on pharmaceutical care activity within a peer review system.  This survey 
intends to identify and categorise the pharmaceutical care activity at two wards at the 
Ayr Hospital.  These quantitative results, along with qualitative investigations 
conducted during the study period, will make the basis for a proposed template for an 
electronic pharmaceutical care plan, which after discussion and revision in focus 
groups, gives an improved application in the electronic prescribing system. 
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1.8.5 The orthopaedic ward  
The survey was sited at the orthopaedic ward (nurses station 10) at the Ayr Hospital.  
The ward has patients with arthritic conditions, patients with fractures or trauma 
admitted through accident and emergency departments and those booked in for 
routine orthopaedic surgery, such as hip and knee replacements.  The station 
contains 36 beds divided into three nursing teams, A, B and post-op room, each 
comprising of two nurses. New patients on admission per week are estimated to be 
approximately 25 patients. One clinical pharmacist is at the orthopaedic ward every 
day from Monday to Friday.  Every Wednesday morning and Thursday afternoon the 
clinical pharmacist meets patients for elective admissions at the pre operative 
assessment clinic and another clinical pharmacist then stays at the orthopaedic ward. 
In the morning (from 9 -13) one or two pharmacy technicians also stays on the 
orthopaedic ward to assess the patients’ own drugs and to label patients medicine. 
 
1.8.6 Taking medication history 
When the clinical pharmacist first attends the ward in the morning all new patients 
admitted are identified. This is done using a print out from the patient administration 
system and also checking with the pharmacy technician which is keeping a diary of 
the patients admitted. When new patients are established the pharmacist makes a 
prioritisation of who to see first based on. If the patient has not been seen by a 
clinical pharmacist recently, which is the case for all patients for elective surgeries 
attending the pre-assessment clinic, the pharmacist first clarifies the patient’s current 
drug regimen. A medicine reconciliation form is used to document the patient’s 
medication history. This includes the regular medicines the patient was on before 
admission, included over-the-counter medicines, herbal medicines etc., and also 
what the plan to if any changes are made. The pharmacist speaks to the patient to 
clarify their current drug regimen. If the patient brought in their own medicines on 
admission the pharmacist often goes through these together with the patient. This 
meeting between the patient and the pharmacist makes it possible for the patient to 
ask questions he/she may have regarding the drug treatment, misunderstandings 
can be easily solved and it also makes it easier for the pharmacist to get an idea to 
which extent the patient is compliant or not to the drug regimen.              
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If the patient is unable to confirm their medication history or has not brought their 
medicines into the ward other sources for getting this information are used. This 
could be the patient’s relatives, which also can contribute with other relevant 
information. Often there may be a discrepancy or uncertainty between the doses 
taken and the medicine label. The pharmacist may then need to contact the patient’s 
General Practitioner to confirm the right medicine history. The patient’s community 
pharmacy, repeating list or blister pack are also used, and more rarely an Electronic 
Care Summary (ECS) System and medical or nurses notes (Table 4). 
 
Table 4 Sources used when taking medication history 
 
Medication history sources 
 
Patient 
Patient’s own drugs (PODs) 
Patient’s relatives 
General Practitioner 




Electronic Care Summary (ECS) System 
Medical/nurses notes 
 
The clinical pharmacist also asks each patient if he/she has any allergies or drug 
sensitivity known. If any drug allergy or sensitivity is identified the generic name of 
the constituents preparations and the nature of the reaction are documented both on 
the paper form and in the electronic prescribing system.  
 
After clarifying the patient’s current drug regimen the pharmacist checks if the 
medication prescribed on the electronic prescribing system on admission is in 
accordance with the confirmed history. Medicines that are already prescribed by the 
doctor on admission are verified by the pharmacist. Any medicines omitted on 
admission can be transcribed by the clinical pharmacist and documented in the 
medical notes. For any other discrepancies in the drugs already prescribed, such as 
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dose, dose timing, formularity etc., the pharmacist withholds the verification of the 
drug on the system, speaks to the doctor to make him/her aware of the actual 
regimen on admission and changes accordingly if there is no reason/intention for the 
alteration. As all patients for elective surgeries have already got their regular 
medication transcribed to the electronic prescribing system by the pharmacist at the 
pre assessment clinic, only a check is needed to see if any changes to the 
medication have occurred in the period of time before admission to hospital. 
 
1.8.7 Pharmaceutical care delivered by the clinical pharmacist at the 
orthopaedic ward 
 
For every patient on the ward that the pharmacist is seeing a pharmaceutical care 
plan is started. Based on a blank clinical note the pharmacist writes in a standard 
setup of information about the patient including present complaints, previous medical 
history, drug history, bloods, drug allergies or sensitivities, over-the-counter (OTC) 
and non-drug treatment (e.g. herbals) the patient is taking and identified care issues. 
All patients admitted are assessed and their new medication orders are checked by 
the pharmacist if they are clinically appropriate. An order not found to be appropriate 
is withhold by the pharmacist in the electronic prescribing system while the issue is 
addressed to the prescriber (Figure 2).  
 
The clinical pharmacist on the orthopaedic ward get into different drug therapy areas 
but as a surgical ward the pharmacist mainly manage issues regarding prophylaxis 
treatment of deep vein thrombosis (DVT), antibiotic cover and pain relief. An example 
can be the check the pharmacist performs to clarify if the patient has indication for 
DVT prophylaxis as per post operation sheet, evaluate the clinical appropriateness 
and monitor for possible side effects. After a major surgery, as a hip- or knee 
replacement, the patient is started on antibiotic prophylaxis. This treatment is 
followed up by the pharmacist by monitoring the patient’s levels of inflammatory 
markers and also ensuring that intravenous treatment with antibiotics is switched to 
oral administration when appropriate. The results from the blood tests taken are 
found in an electronic database. Ensuring effective treatment of the patient’s pain 
after surgery is also essential. The pharmacist checks that the patient is prescribed 
an optimal combination of analgesics while inpatient and also at discharge. The 
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nurse staff is an important collaborator in the assessment of the patient’s effect, side- 
effect and need of medication.      
 
Table 5 Shapes of boxes used in process mapping 
 




This figure is used to describe a process being started 
or terminated 






The square is used to describe processes undertaken.    
If the square has to lines on the sides the boxes it is 
referring to is a predefined process.   





This figure is used to describe the part of the process 
that includes some form of documentation 






The diamond is used to describe a decision being 
made. The decision is often answered with yes or no.  
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Patient has already been 
seen by a pharmacist 
on the pre-op clinic or 
another ward and has a 
pharmaceutical care plan
Patients’ current drug 
regimen clarified    
All regular medicines 
prescribed on the EPS 
by doctor?
Pharmacist checks if 
all regular medicines are 
appropriate treatment for 










in drug history that 














Pharmacist continues to monitor 
the drug treatment 
Outstanding issues followed up 
to individualise and make the 
patient’s treatment optimal 







and verifies medicines on 
the EPS and write in the 
medical notes
Prescription verified by 
pharmacist on the EPS
Pharmaceutical care delivered by the pharmacist on the orthopaedic ward
 
 




1.8.8 The orthopaedic ward as a medicines re-design ward 
At Ayr Hospital the patients’ own medicines and one-stop dispensing schemes are 
implemented in the two medicines re-designed wards which include the orthopaedic 
ward. The self-administration of medication scheme is not yet introduced. Patients for 
elective admissions bring in their medication to be registered by the pharmacist or 
admitting nurse at the pre-assessment clinic. The pharmacist gives these patients 
information about the scheme, including a leaflet, and a consent form is completed if 
the patient accepts that their own medicines are used during the stay in hospital. The 
patient also gets a bag to bring in the medicines on admission. 
 
When admitted to the ward the medicines brought in are stored in a locked cupboard 
at the patient’s bedside (Figure 3). If the patient has not brought the medicines into 
hospital, which primarily is the case for emergency admissions, the patient relatives 
is asked to bring them in and consent is taken from the patient to use them in 
hospital. This is generally a task for the pharmacy technician, but for admissions in 
the weekend, when no pharmacy staff is on ward, the nurse staff ensures that this is 
done. The consent to use the patients’ own medication encompasses also the 
possibility to destroy the medicines. If this consent is refused, which is very rarely the 
case at the orthopaedic ward, all the patients’ own medicines, discontinued 
medicines included, is stored in the bag in the patients’ bed-side locker and all 
medicines used while in-patient are ordered from the pharmacy.   
 
The medicines brought into hospital by a patient are assessed by a pharmacy 
technician using a form considering all the criteria the patients’ own drugs must meet 
to be suitable for use while the patient is admitted. At the Ayr Hospital medicines in 
compliance aids that is a blister pack can be used provided that it is clearly marked 
with the name of the medicine, strength and expire date, while medicines in other 
compliance aids as refillable boxes are not used. Controlled drugs brought in on 
admission that are found suitable are registered in a PODs controlled drugs protocol, 
stored in the wards controlled drugs cabinet and administered to the patient as long 
as indicated. PODs brought in on new admissions during weekends, when no 
pharmacy staff is on ward, should be assessed by a trained nurse before they are 
administered. This is however a part of the scheme where the practice is not as 
intended. The medicines for these admissions out of pharmacy opening hours are 
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administered to the patient without any assessment of their suitability.  The 
assessment is not done until the next working day for the pharmacy technician. This 
shows the importance of establishing an efficient co-operation between nursing and 
pharmacy teams, and it is recommended from other wards where such schemes are 
implemented to appoint a change management nurse to facilitate this process(43,44). 
 
For each patient the clinical pharmacist checks if the medicine the patient brought in 
is to be continued while in hospital or if the dose has been changed on admission. 
When the clinical pharmacist is verifying the medicine on the electronic prescribing 
system a box for “Patients’ own medicine” is ticked off to display for discharge what 
medicines was brought in to hospital and not. The clinical pharmacist informs the 
technician on ward that the patient’s medicines are verified and about any changes 
made. The medicines are then labelled accordingly to changes made and those 
found not suitable for use while in-patient are labelled as such and returned, together 
with medicines stopped, to the pharmacy for destruction.  
 
As a part of the medicines re-design service the one-stop dispensing scheme is 
implemented at the orthopaedic ward. After the assessment of the suitability of the 
patient’s own drug the pharmacy technician checks if the amount is sufficient to take 
away on discharge. Additional medicines needed, as well as substitution for the 
medicines found not suitable for use and medicines commenced on admission, are 
supplied from either the ward medicine stock or in most cases ordered and sent via 
pneumatic postal tube which dispatches from the pharmacy to the orthopaedic ward. 
If the patient has enough of a medicine at home, and therefore does not need further 
supply on discharge, or if the patient wants a medicine returned although it was 
found unsuitable for use in hospital the technician makes a note in the electronic 
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Figure 3 Process map of handling of patients’ own drugs (PODs) on the orthopaedic ward 
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1.8.9 Discharge planning 
When a patient is ready for discharge the doctor fills the electronic discharge 
prescriptions for medicines to take away for the patient (Figure 4). A printout of this is 
given to the clinical pharmacist who clinically checks and verifies each of the patient’s 
prescriptions both electronic and on paper if no changes has to be made. Any 
medicines that are missed out on the discharge letter are added by the pharmacist if 
it is confirmed to still be required. For prescriptions on laxatives and analgesics, the 
patients’ administration details during the stay is often checked and staff nurses’ are 
asked to ensure the supply is needed on discharge. If there still are any outstanding 
care issues in the care plan these are also dealt with. Information to the patient’s 
General Practitioner regarding any medicines started, changed or discontinued 
during the stay is written in the discharge letter.   
 
When the prescription is verified the clinical pharmacist informs the technician who 
gets the patient’s medicines from the bedside locker and checks if any additional 
medicines need to be supplied and ordered from the pharmacy. At the Ayr Hospital 
they ensure that patients have a minimum of 14 days supply on discharge. The 
technician on the ward labels the medicines before a checking technician or the 
clinical pharmacist is doing a second check of the medicines. 
 
Finally the medicines are given to the patient with information from either a technician 
or the pharmacist. If poor compliance is identified during the stay the pharmacist 
often makes a medication chart including a list of each of the patient’s medicines 
name, what they do and at what time they should be taken. Before the patient is 
discharged the pharmacist or a technician goes through the list and possible 
misconceptions can be solved. The patient counselling and education are unique and 
important contributions from the pharmacy staff to the patient’s pharmaceutical care.  
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Figure 4 Process map of discharge planning at the orthopaedic ward  
       
 49 
2 Aims and objectives 
 
2.1 Aims 
• To review two cohorts of patients in terms of pharmaceutical care delivered 
by examining free text electronic records and categorising care issues into a 
proposed reporting system.  
 
• To test the validity and the utility of the reporting system, by using qualitative 
research methods in an action research process.  
 
• To propose a template for an electronic pharmaceutical care plan that meets 
defined criteria for service developments including non-medical prescribing. 
 
2.2 Objectives 
1.  Review the literature on orthopaedic, the application of electronic health 
records; and the documentation of clinical pharmacy activities to inpatients and 
at the point of discharge from hospital. The usage of a pharmaceutical care 
issue categorisation system will also be a focus in the review as will be the 
introduction in the UK of non-medical prescribing. 
 
2.  To describe the operational delivery of the clinical service using a process map 
that is validated by pharmacists and technicians involved in care delivery. 
 
3.  Identify documented care plans from samples of patients receiving 
pharmaceutical care during January 2008 to March 2008 using the electronic 
care monitoring system. Identify context and outcomes of each care plan by 
obtaining additional information from paper case records and through dialogue 
with clinical pharmacist authors to overcome any gaps in the free text electronic 
records. 
 
4.  Modify existing categorisation system used at the University of Strathclyde to 
increase the robustness and clinical usefulness. Develop a guideline for use of 
the system. Test utility and validity of the modified system.  
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5. Conduct a contents analysis in a formal survey of the care plans in order to 
categorise the care issues. 
 
6.  Demonstrate inter-rater reliability in the categorisation of the care issues in the 
survey. 
 
7.  Conduct a survey of prescribing activity to measure prescription turnover and to 
quantify exposure of each patient to medication during their stay. 
 
8.  Evaluate proposed templates in terms of validity and utility for reporting care 
plans using an action research approach. Survey findings will be reported to the 
clinical pharmacy team over a series of meetings, in order to revise the 
template in response to the feedback obtained. 
 
9.  Draw conclusions on the role of the audit findings in defining future application 




2.3 Ethical approval 
Approval to undertake the survey was granted from the Ayrshire and Arran Health 
Board Ethics committee. This was made late in January and due to this the data 
gathering did not start before the first days of February.  
2.4 Inclusion criteria  
For inclusion in the survey, patients had to meet the following criteria; 
• New patients identified at the orthopaedic ward during the recruitment period 
between the 4th of February and the 17th of March 2008. 
• Patients seen by a clinical pharmacist at the orthopaedic ward with a 
pharmaceutical care plan started.  
• Patients able and willing to sign a consent form.  
 
The patient inclusion at the cardiology ward had the same criteria and recruitment 
period as the orthopaedic ward. 
2.5 Data collection period 
The recruitment period was between the 4th of February and the 17th of March 2008. 
Data from the pharmaceutical care plans was collected until the last patient included 
was discharged in the middle of April 2008. 
2.6 Investigators 
The investigator is in her 5th and final year of her degree as Master of Pharmacy at 
the University of Tromsø in Norway, and this project was conducted in partial 
fulfilment of this degree.  
 
Additional researchers involved at the time this work was undertaken include 
Stephen Hudson, Professor of Pharmaceutical Care at the University of Strathclyde 
(Academic Supervisors), Carl Fenelon, Lecturer in Clinical Practice, Pharmaceutical 
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Care Health Service Unit at the University of Strathclyde (Co-Supervisor), Gillian 
Jardine, Clinical Pharmacy Manager at the Ayr Hospital (Clinical Co-Supervisor). The 
part of the project at the Ayr Hospital was conducted in partnership with co 
investigator Reidun Os Husteli. The development of guideline for use of the modified 
system was done through co-operation with Reidun Os Husteli, Marit Bergheim 
Christensen and Kari Jansdotter Husabø. 
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3 Methods 
3.1 Literature review 
The literature on the clinical specialities was obtained from research in electronic 
databases as PubMed, from referred articles in previous work done by others(45,46) 
and relevant references from the clinical pharmacist at the Ayr Hospital.  National 
strategy plans and programmes, internal guidelines for the NHS Board and the 
hospital (e.g. Joint Formularies) also formed the basis literature for the survey. 
 
3.2 Produce process maps of the delivery of pharmaceutical care, 
use of patient’s own drugs and discharge  
The investigator observed the clinical pharmacists at the medical receiving ward, the 
cardiology ward, the pre-assessment clinic and the orthopaedic ward at the Ayr 
Hospital over two weeks during October 2007. Most of this time with observations 
was spent on the ward where the survey was done to better understand how the 
pharmaceutical care is given to inpatients there. The investigator also spent in all a 
one day period in the dispensary at the pharmacy and also at the medicines re-
design ward together with one of the pharmacy technicians to better understand how 
medicines are supplied and delivered at the hospital cardiology ward, where patients 
own drugs (PODs) not are used and at the orthopaedic ward, where PODs are used. 
  
Process maps were made as graphical presentations of the processes including 
pharmaceutical care delivered, the supply and administration of drugs and the 
discharge. The investigators was co-operating on making a process map of how the 
patient’s own drugs was used of in practice. Process maps showing the 
pharmaceutical care delivered by pharmacists was made by the investigator in the 
setting where the survey was carried out. These descriptions were made based on 
both the major objectives in the processes identified during the observation period, 
and information gathered from the pharmacists and technicians involved in the 
provision of pharmaceutical care and the supply and administration of drugs.  
 
There were standard operating procedures (SOPs) in place for the different 
processes that is a part of the pharmaceutical care delivered at the wards and these 
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were also used in the making of the process maps. The investigator made sketches 
of the processes including exceptions, errors and risk factors and asked the 
pharmacist involved in the process to comment on these. In total the process maps 
were corrected and commented on three occasions to ensure validated process 
maps. The mapping was done by using specialised software, Microsoft Visio 2003.  
 
3.3 Collect patient data to describe prescription activity and 
pharmaceutical care profile of the acute receiving ward 
Measurements of the prescription turnover and quantification of exposure of each 
patient to medication during their stay was to be studied and analysed separately 
using methods developed by CF and SH. These numbers will be gathered 
retrospectively for the cohort entering the audit survey, based on statistics generated 
from the electronic prescribing system. 
 
3.4 Propose a pharmaceutical care plan template 
3.4.1 Training period 
The investigator was trained by SH and CF on making paper profiles of patients in 
the period from November to December 2007. A patient paper profile, based on care 
plan templates used in the training of pharmaceutical care at the University of 
Strathclyde, was developed to capture the information found relevant for the survey. 
The investigator did this training together with co investigator ROH based on the 
cardiology ward. In this period previous to the survey the investigators gained 
experience in patient data gathering from the electronic prescribing system, medical 
notes etc. and a total of 30 patient paper records from the orthopaedic ward and the 
cardiology ward were made. During this training period the investigator worked 
alongside the pharmacist SMCK at the orthopaedic ward.  
 
3.4.2 Data gathering  
Data to identify patients in the recruitment period was gathered from both the 
electronic prescribing system and the patient administration system census and also 
the daily bed state form at the ward, since patients transferred or discharged during 
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the weekend no longer will be in the prescriber database for the ward on Monday. 
The investigator quantified the number of patients admitted, the number of patients 
seen by the pharmacist on ward, the number of patients missed out in the weekend 
and the number of patients where consent was not received including the reason for 
that.   
 
The investigator went to every patient that was identified suitable to consent with an 
information sheet about the survey and asked the patient to sign a consent form 
(appendix 3). The patients included in the survey were followed until they were 
discharged, transferred to another ward or died, and so the survey lasted until the 
last patient had left the ward. Patients that were readmitted to the ward in the 
recruitment period were counted as one patient if the same pharmaceutical care plan 
was continued on. The daily bed state form on the ward was used to confirm both 
where the patient was admitted from and discharged to. Patient data was 
anonymised and the investigator kept personal data for the patients included in the 
survey in a book with an identification number belonging to each patient. This made it 
possible for the investigator to identify the patients in order to gather clinical relevant 
information and at the same time maintain confidentiality. 
 
All patients included in the survey had an electronic paper profile written by the 
investigators with information drawn from: 
 
a: Pharmacist authors’ free text notes within the electronic prescribing system 
b: Patients’ medical records 
c: Patient profile notes 
d: Discharge letter 
e: Interviews with the pharmacist authors with reviews of the paper profiles to verify 
the accuracy of the description of care delivered. 
 
The above approach overcome gaps in the free text electronic records, and 
document the care delivered. The investigator kept a copy of the free text notes 
written by the pharmacist and the medicines prescribed for each patient that was 
reviewed continuously for any updates during the hospital stay. The investigator used 
the patients’ medical records to get data about previous medical history, drug history 
and social history. The discharge letter was available from the dispensary and used if 
relevant for the patient. Patients’ clinical characteristics and care issues was clarified 
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according to an action research approach where the investigator regularly talked with 
the pharmacists involved to identify the actions that actual had been taken in the 
situation. 
 
3.4.3 Critically review and feedback on the care plan template  
The patient paper profile was intended to serve as a basis for making a care plan 
template within the electronic prescribing system. The investigator used action 
research as a method, through a group meeting, for giving feedback on the template. 
The meeting was held at the pharmacy department at the Ayr Hospital the 21st of 
April 2008 with six of the clinical pharmacists participating. The investigator 
presented, together with co investigator ROH, the categorisation system used for 
categorising the care issues, key figures of the results from the survey and ideas for 
a care plan template. The feedback obtained from this meeting made the basis for 
the care plan template draft presented on the focus group held at the University of 
Strathclyde in Glasgow the 28th of April 2008. The views generated during the first 
group meeting were documented by notes taken of the investigators while the 
comments on the focus group were tape recorded.   
 
3.5 Practical application and evaluation of the existing 
categorisation system 
3.5.1 The modification of the categorisation system 
An existing categorisation system to describe pharmaceutical care developed and 
used at the University of Strathclyde was evaluated and modified through 
cooperation with co investigators ROH, MBC and KJH, all doing projects on similar 
surveys in four different hospital settings. The system was based on analysing 
documented care issues and assigning them into the categories; 
 
 
a: Drug therapy problems (Cipolle, Strand)(10) 
b: Check or Change category (Strand, McAnaw)(11) 
c: Quality Assurance Descriptors (McAnaw, Hudson)(11) 
 
Literature on drug therapy problems, categorisation and categorisation systems was 
reviewed to better comprehend all aspects of pharmaceutical care or clinical 
 57 
pharmacy(10,11). Modifications of the existing categorisation system were made with 
the purpose to make it more applicable in a clinical setting and ensure that it covered 
all aspects of pharmaceutical care. Ideas generated from the literature review, paper 
records from the orthopaedic ward and the cardiology ward and through several 
research meetings with SH, CF, ROH, MBC and KJH were incorporated. This 
modified system was presented in a guideline describing the categorisation system 
(Appendix 6) 
 
The categories of Drug Therapy Problems (DTP) used was those defined in the book 
Pharmaceutical Care Practice – The Clinician’s Guide (10) by Cipolle et al. The 
examples given within each category was modified in the guideline to enhance the 
correlation between the heading of the DTP subcategories and the type of care 
issues included in them (See appendix 5). An additional subcategory Unclassified 
was added in order to categorise care issues where the change is not patient 
specific. For instance due to non-adherence with local formularies and with only cost-
control implications, rather than medication safety or effectiveness (Table 6). 
 
Table 6 Modified categories of Drug Therapy Problems 
(from ‘Guideline for categorisation of pharmaceutical care issues’, Appendix 6) 
 
Categories of Drug Therapy Problems 
  
1 Unnecessary drug therapy 
2 Need for additional drug therapy 
3 Ineffective drug 
4 Dosage too low 
5 Adverse drug reaction 
6 Dosage too high 
7 Inappropriate compliance 
8 Unclassified i.e. Non-DTP  
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The four Check categories were kept as they were originally while the existing 
category Change was divided into two types of subcategories; Change in Drug 
Therapy Process and Change in Drug Therapy (Table 7). This division was made on 
whether the care issue was associated with a change in the care process around the 
patients’ drug treatment or directly to the drug therapy. The subcategories that 
related to the care process in the existing change system under the headings ‘Patient 
behaviour’ and ’Patient data handling’ (see table 3) were included in Change in Drug 
Therapy Process, while the existing subcategories under the existing heading 
‘Treatment plan changes’ were included in the Change in Drug Therapy category. 
The number and designation of the subcategories were further changed to be 
comprehended more easily. The background for the division was that the 
investigators found that while a Change in the Drug Therapy could be assigned a 
recognisable Drug Therapy Problem category the impact of the outcome of care 
issues in the care process was hard to determine and too speculative to lead to a 
Drug Therapy Problem category.  
 
Table 7 Modified categories of Change 
(from ‘Guideline for categorisation of pharmaceutical care issues’, Appendix 6) 
 
Change in  
Drug Therapy Process categories 
 Change in  
Drug Therapy categories 
Change made to:   Change made to: 
Clinical (shared) record of patient 
characteristics 
 Drug selection  
(starting new or changing drug) 
 













Health care team member(s) 
information/education  
   
Duration 
   
Stop drug temporarily/permanently 
   




The existing definitions of the Quality Assurance Descriptors were modified to be 
more comprehensive for practical use. To emphasise what the subcategories for the 
Quality Assurance Descriptors was describing in the patients treatment loop they 
were designated Time Perspective and Degree of Change (Table 8). The modified 
definitions in Time Perspective specifies to a greater extent at which stage in the 
quality assurance loop the check is done. The investigators also modified the 
definitions in Degree of Change to make it easier to differentiate between the extent 
of changes and the categories assigned to them. The new definitions are found in the 
guideline (Appendix 6)  
 
Table 8 Quality Assurance Descriptors categories with designated names 
(from ‘Guideline for categorisation of pharmaceutical care issues’, Appendix 6) 
 
Categorisation of checks  
according to where they are done in 
the quality system feedback loop 
 Categorisation of changes  
according to the extent of the change 
in the quality system feedback loop 
 
Time perspective  Degree of Change 
Verification  Adjustments 
Monitoring  Modification 
Confirmation  Reviews (prompting a review) 
 
This pilot phase included an initial assessment of researcher care issue 
categorisation by conducting a peer-review inter-rater reliability testing with ROH, 
MBC and KJH to get an idea of whether the categorisation coincides among the 
different researchers.  
 
3.5.2 The development of a guideline describing the categorisation system 
The guideline for use of the modified system was developed through cooperation 
with ROH, MBC and KJH. There was an existing set of guidelines devised by the 
Pharmaceutical Care Health Service Unit at the University of Strathclyde (see 
appendix 5). This was extended by the investigators to fully describe the 
categorisation of a care issue into the triangularised system. As a result of the 
modifications of the existing guideline the investigators came to that each care issue 
should be categorised in three such dimensions (see table 9); 
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1. As either a Check or a Change; where a Change may be a Change in the Drug 
Therapy Process or a Change in Drug Therapy, depending on the outcome.  
 
The care issue is further categorised into 
 
2. Quality Assurance Descriptors; which indicate a care issue’s position in the 
process of delivering pharmaceutical care (Time Perspective).  
If the care issue is a Change in Drug Therapy this category also describes the 
extent of the change made (Degree of Change).  
 
The third dimension in the system is 
3. Drug Therapy Problem and only a care issue identified as a Change in Drug 
Therapy was categorised as such. 
 
Table 9 Categorisation system of pharmaceutical care issues 
 
 
Pharmaceutical Care Issue 
 
Check or 
Change? Check Change 
 
 
Change in Drug 
Therapy Process 
Change in Drug Therapy 
Drug Therapy 
Problem 













If the outcome of the care issue is unknown, the care issue is incomplete and can not 
be categorised in the categorisation system. Care issues regarded as part of the 
standard procedure, as for example general checks for dose and indication at 
admission, during the stay and at discharge, is not included. 
 
Characterisations of the subcategories within each section were made in the 
guideline to clarify which of the care issues that would be assigned to it. The 
guideline also includes a description of the way the pharmaceutical care delivered 
can be thought of as a quality assurance system. To make the definition of 
‘verification’ in the ‘Time Perspective’ applicable for different clinical settings the 
pharmacist can meet the patient, the ‘verification’ was more precisely described to 
occur when a patient is either admitted, when the pharmacist first see the patient or a 
new treatment is started. A selection of issues from the patient profiles made in the 
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training period from November to December 2007 was gathered to exemplify how 
different care issues are categorised according to the guideline.  
 
3.5.3 Evaluation of the categorisation system 
The investigators used a focus group as a method in order to get feedback on the 
completeness and usability of the modified categorisation system. The focus group 
was held at the University of Strathclyde in Glasgow on the 28th of April 2008. The 
invited participants were clinical pharmacists connected to different clinical settings at 
the Ayr Hospital and the Glasgow Royal Infirmary where the surveys had been 
conducted. In addition the supervisor of the group was participating.  
 
The invited participants received the guideline and the examples of categorisation of 
care issues in advance of the focus group. The investigators were the moderators of 
the focus group. The categorisation system and the results from the surveys at the 
four different clinical settings were presented for the participants. The presentation 
was structured in to the results from the surveys compared between the four wards 
belonging to the different categories. A set of pre defined questions were asked 
during the presentation to encourage discussion and to get feedback from the 
participants on the categorisation system. The focus group was audio recorded and 
transcribed by the investigators afterwards. 
 
3.6 Categorisation of care issues  
3.6.1 Training in the practical application of the categorisation system 
The investigator was together with co investigator ROH categorising the care issues 
found in the 30 patient paper records from the care plan training period from 
November to December 2007. The training on categorising the care issues was done 
both by Steve Hudson and Carl Fenelon and through the development of the 
guideline for the categorisation system.  
 
Care issues generated from the survey populations care plans was characterised by 
using the triangulated system described above. In addition the investigator and the 
co investigators quantified care issues related to drug interactions and care issues 
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where the pharmacist made a recommendation to the prescriber regarding changes 
in the patient’s drug therapy. If the recommended change is carried out the care 
issue is categorised as a Change in Drug Therapy Process or a Change in Drug 
Therapy. On the other hand, if the change of different possible reasons is not 
followed up the care issue will be categorised as a Check. None of these data were 
captured in the categorisation system but were included in the database.    
 
3.6.2 Database 
A database was used to key in all the care issues identified from the survey 
population and further categorise each of them according to the modified 
categorisation system. The database allowed the investigator to more easily do 
statistical analysis on the data, do queries and transfer data to other program for 
further analysis. The database is made in Microsoft Access®    
 
3.6.3 Inter-rater reliability testing 
An inter-rater reliability test to demonstrate the inter-rater reliability in the 
categorisation process between the investigator and co researcher ROH was done. 
The investigator and co researcher picked a randomly sample of 50 care issues from 
each of the two survey populations. These 100 care issues were categoried by both 
the investigator and ROH. The inter-rater reliability of the categorisation of care 
issues generated from the survey was demonstrated for the categories Checks, 
Changes in Drug Therapy Process and Changes in Drug Therapy and the categories 
within the Quality assurance system (See Table 10). These system sections were 
therefore analysed separately to demonstrate the validity within each of them.  
 
Table 10 Parts of the system tested for inter-rater reliability for categorisation of care issues 
 
 
Checks, Changes in Drug Therapy Process, Changes in Drug Therapy 
 
Subcategories within Checks, Changes in Drug Therapy Process, Changes in Drug Therapy 
 
Verification, Monitoring, Confirmation 
 
Adjustment, Modification, Review 
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3.6.4 Cohen’s Kappa 
The inter-rater reliability was analysed using Cohen’s kappa statistic. Cohen’s kappa 
(κ) is a measure of the agreement between two raters which also takes into account 
the agreement occurring by chance. The data is arranged in a matrix with one rater 
vertically and the other horizontally(47). Different parts of the system with different 
numbers of categories were tested and the size of the matrix therefore varied from a 
3x3 matrix to a 16x16 matrix. The calculation of the value of kappa is shown for a 3x3 
table (Table 11) 
 
















Checks 1.1 1.2 1.3 Y1 
Changes in Drug 
Therapy Process 
2.1 2.2 2.3 Y2 
Changes in Drug 
Therapy 
3.1 3.2 3.3 Y3 
Total X1 X2 X3 N 
 
 
The number of issues where exact agreement is observed among the raters is the 
sum of the values in 1.1, 2.2 and 3.3. This can be expressed as the relative observed 
agreement (po) which is: 
 
number of exact agreement observed 1.1 + 2.2 + 3.3 
po = total number observations 
= 
N 
   
 
The next step is to calculate the number of agreements that would be expected by 
chance. For each square this is the product of the total of the relevant column (X) 
and the total of the relevant row (Y) divided the total number of observations (N). The 
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total amount of expected observation by chance is expressed as the relative 
expected agreement (pe) which is:   
 
    (Y1*X1) (Y2*X2) (Y3*X3) 
number of exact agreements expected by chance N N N 
pe = total number observations = N 
The raters agreement and the value of kappa (κ) is then calculated as the equation: 
 
 
If the raters are in complete agreement then κ = 1. If there is no agreement among 




po - pe 
Kappa (κ) = 




4.1 Pharmaceutical care plan template 
4.1.1 Group meeting with critically review and feedback on the care plan 
template  
The group meeting with the clinical pharmacists was held at the Ayr Hospital on the 
21st of April 2008. The investigator and co investigator ROH presented the care issue 
categorisation system, results from the survey and ideas for how a care plan 
template within an electronic prescribing system could look like. Different suggestions 
for how each section of the care plan template could be presented were introduced 
for the clinical pharmacists and they gave the investigators feedback on which 
solution that would possibly be the best in their work. The group suggested that the 
‘Medicine Reconciliation Form’, now used on paper by the pharmacist when taking 
the medication history for a new patient, could be implemented in the care plan 
template. The meeting led to different ideas that are presented in table 12. It was 
commented that the free text document used by the pharmacist in the electronic 
prescribing system today is called a ‘note’ instead of what it actually is; a care plan. 
The participants pointed out that their greatest demand within the care plan 
documentation is an improved section for the care issues.   
 
 
Table 12 Ideas generated from the group meeting for discussing the care plan template 
 
• Each pharmacist have an individual profile within the electronic prescribing 
system 
• Relevant parts from the ‘Medicine Reconciliation Form’ used today should be 
implemented into the template 
• Information as 'Presenting complaints', Past medical history' and 'Relevant drug 
history' can be presented as free text boxes 
• Tick boxes for often used sources and free text space for other sources are 
wanted. Only sources ticked of will later appear in the care plan 
• Relevant information already found in the electronic prescribing system, as 
allergies and patient demographics should be implemented in the care plan  
• Other functions that calculates eGFR, digoxin level etc. should be available  
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Ideas related to the care issues: 
• Actions made in the electronic prescribing system, e.g. when the pharmacist 
withholds a verification of a drug should be automatically linked to the care plan 
• ‘Shortcuts' where the pharmacist can choose predefined texts for making care 
issues 
• Each issue's review date outlines the priority of these. The care issues can be 
sorted in the care plan after this review date   
• Issues relevant for discharge can be marked by ticking the discharge box and be 
placed between the active and inactive care issues.  
• The sections in the ‘Medicine Reconciliation Form’, e.g. notes about the patient’s 
compliance, need for compliance aid, number to community pharmacy, if the 
patient can self administer drugs etc. are information that should be presented 
as care issues  
        
4.1.2 The care plan template draft 
The investigator and co investigator ROH made a care plan template draft based on 
the ideas generated at the group meeting at the Ayr Hospital (Figure 5). This draft 
was presented on the focus group held at the University of Strathclyde in Glasgow on 
the 28th of April 2008 with clinical pharmacists participating. It was emphasised from 
one of the participants that the pharmaceutical care planning does not have the same 
focus in other parts in UK as it has in Scotland and that this is a hindrance to the 




    
 
PHARMACEUTICAL CARE PLAN Review  
[review date]  
    
 
 
[Patient identification]  
    
 
Presenting Complaints  
[free text box] 
[sign/ date] 
 
    
 
Past Medical History  
[free text box] 
[sign/ date] 
 
    
 
Relevant Drug History  
[free text box] 
[sign/date] 
 










specify if not oral 
Dose Frequency Sign 
 











specify if not oral 
Dose Frequency Sign 
 
     [sign/ date]  
       




    
 
 Medicine/Substance Reaction Sign  
   [sign/ date]  
     
     






  GP surgery  PODs [sign/ date]  
  GP letter  Nursing home   
  Discharge letter  Medical notes   
  Patient  Electronic Care Summary System  
  Patient’s family [freetext box]  
  Community pharmacy [freetext box]  
     




  Date Date Date  Date Date Date Date Date  
 Weight    BP      
 Height    HR      
 BMI          
 
 
Laboratory Results  
   Date Date Date Date Date Date  
 Test Range Units        
 K 3.5-5.0 mmol/l        
 Na 135-145 mmol/l        
           
 Free text  
 [freetext box]         
          
          
 
 
Pharmaceutical Care Issues  
 
  Active 

























 Discharge  
 












 Discharge  
 
Figure 5 Pharmaceutical care plan template draft 
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4.2 Pharmaceutical care data from the survey 
4.2.1 Ward characteristics 
There were 90 patients included to the survey during the recruitment period on the 
orthopaedic ward from 04.02.08 to 17.03.08. This formed a part of 68.7% of the 
totally 131 patients that were seen by a ward pharmacist and got a care plan started 
in the same time period. The 41 patients excluded although they were seen by a 
pharmacist were so because the patient was not willing (n=6) or unable to consent 
(n=24), or that the investigator did not see the patient, due to a short stay on the 
ward, and therefore did not got consent from the patient before he/she was 
discharged home or to another ward (n=11). The count of patients that were admitted 
and discharged during the same weekend was found to be one. The orthopaedic 
ward had totally 184 admissions during the recruitment period.  
 
4.2.2 Comparison of the orthopaedic ward and the cardiology ward 
In table 13 the number of drugs on admission per patient is presented from both the 
orthopaedic and cardiology ward. The sources of information used to obtain drug 
history are those documented in the care plan. The different sources gathered in 
‘Other’ include nursing home, medication record, box filled by dispensing doctor, 
Electronic Care Summary and repeating list.  
 




Orthopaedic Cardiology p value 
(t test) 
Total drugs on admission 468 398  
Mean  (CI) 5.2 (4.4-5.9) 5.6 (4.4-6.8) 0.53 
Median (IQR) 5.0 (2.3-7.0) 4.0 (1.5-9.0)  
Range 0-14 0-23  
Frequency distribution (%) 
  
 
Sources of information used to 
obtain patient drug history  (n=90 patients) (n=71 patients) 
 




                                         1 23 (25.6) 26 (36.6)  
2                          52 (57.8) 40 (56.3)  
                                            3 5 (5.56) 5 (7.0)  
                                            4 1 (1.1) 0 (0)  
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(Table 13 cont.)    
Actual sources used  (n=146 sources) (n=123 sources)  
 




Patient’s own drugs (PODs) 40 (27.4) 14 (11.4)  
Patient’s relatives 2 (1.4) 5 (4.1)  
General Practitioner 19 (13.0) 16 (13.0)  
General Practitioner letter 8 (5.5) 8 (6.5)  
Community Pharmacy 2 (1.4) 5 (4.1)  
Discharge letter 4 (2.7) 12 (9.8)  
Notes 0 (0.0) 7 (5.7)  




4.2.3 Categorisation of care issues  
The survey was done at the orthopaedic ward with 36 beds and the cardiology ward 
with 30 beds. The inclusion criteria and period for the survey at the two settings was 
the same. The patient characteristics were similar between the two settings. There 
were 90 (40% males) patients included at the orthopaedic ward and 71 (63% males) 
patients included at the cardiology ward to the survey. The mean length of stay was 
longer at the orthopaedic ward than the cardiology ward. None of these differences 
between the two groups were statistically significant (Table 14).        
 
The total number care issues per patient (CI) identified was 3.0 (2.6,3.4) on the 
orthopaedic and 5.3 (4.2,6.5) at the cardiology ward. This result was found to be 
statistically significant with a p<0.001. The distribution of the care issues into the 
categories Check, Change in Drug therapy process and Change in Drug Therapy is 
also presented in table 14.   
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Table 14 Comparison of patient characteristics and pharmaceutical care activity at the 


























































































































































α=0.05 have been used for 95% confidence interval (CI). p>0.05 means that the null 
hypothesis remains, and that there is no demonstrable difference between the two 
populations, while a p<0.05 means that there is a 95% likelihood of a real difference 
between the two populations based on the comparison of the two samples. The 
closer the p-value approaches zero respectively, the greater the likelihood of a real 









Table 15 Pharmaceutical care issues within the quality assurance descriptor categories Time 
Perspective and Degree of Change: Comparison of orthopaedic and cardiology ward 
             Orthopaedic          Cardiology   
 n %         n % p value 
    (95% CI)   (95% CI) (chi square) 
Check 
Verification 27 30.7      
(22.0, 41.0) 
68 25.5      
(20.6, 31.0) 
0.7885 
      
Monitoring 50 56.8      
(46.4, 66.7) 
199 74.5      
(69.0, 79.4) 
< 0.0001 
      
Confirmation 22 25.0      
(17.1, 35.0) 
0 0.0         
(0.0, 1.7) 
< 0.0001 
Total 88  267   
      
Change in Drug Therapy Process 
Verification 69 89.6      
(80.6, 94.9) 
49 71.0      
(59.4, 80.4) 
0.0058 
      
Monitoring 8 10.4        
(5.1, 19.4) 
20 29.0       
(19.6, 40.6) 
0.0058 
      
Confirmation 0 0.0         
(0.0, 5.7) 
0 0.0         
(0.0, 6.3) 
< 0.0001 
Total 77  69   
            
Change in Drug Therapy 
Verification 55 58.5      
(48.4, 68.0) 
22 52.4      
(37.7, 66.6) 
0.5756 
      
Monitoring 30 31.9      
(23.3, 41.9) 
15 35.7      
(22.9, 50.9) 
0.6961 
      
Confirmation 9 9.6         
(4.9, 17.4) 
5 11.9      
(47.3, 25.5) 
0.7619 
Total 94  42   















      
Modification 13 13.8        
(8.1, 22.4) 
9 21.4      
(11.5, 36.2) 
0.3153 
      
Review 0 0.0         
(0.0, 4.7) 
2 4.8         
(0.5, 16.7) 
0.0938 
Total 94  42   
 
Only care issues categorised into the Change in Drug Therapy will be assigned one 
of the quality assurance descriptors ‘adjustment’, ‘modification’ or ‘review’ (Table 15).  
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Table 16 Pharmaceutical care issues within Check, Change in Drug Therapy Process and 
Change in Drug Therapy : Comparison of orthopaedic and cardiology ward 
 
  Orthopaedic Cardiology   
 n % n % P value 
    (95 % CI)   (95 % CI) (chi square) 
 Check  
Medication need inquiry 59 59.6 27 10.1 < 0.0001 
  (49.7, 68.7)  (7.0, 14.4)  
      
Effectiveness inquiry 15 15.1 83 31.1 0.0021 
  (9.3, 23.6)  (25.8, 36.9)  
      
Safety inquiry 23 23.2 142 53.2 < 0.0001 
  (16.0, 32.5)  (47.2, 59.1)  
      
Compliance inquiry 2 2.0 15 5.6  0.1734 
  (0.1, 7.5)  (3.4, 9.1)  
            
 Change in Drug Therapy Process  
          
Clinical (shared) record of patient 
characteristics 
0 0.0          
(0.0, 5.7) 
11 15.9         
(9.0, 26.5) 
 0.0002 
      
Clinical (shared) record of drug 
history 
63 81.8       
(71.6, 89.0) 
37 53.6       
(42.0, 64.9) 
0.0003 
      
Continuity of information / care 
between clinical settings 
5 6.5          
(2.5, 14.7) 
11 15.9        
(9.0, 26.5) 
0.1093 
      
Level of patient monitoring 3 3.9 2 2.9  1.0 
  (0.9, 11.3)  (0.2, 10.6)  
      
Health care team member(s) 
information/education 
6 7.8          
(3.3, 16.3) 
8 11.6         
(5.7, 21.5) 
0.5755 
 Change in Drug Therapy  
 
Drug selection      













      
Dose 6 6.4 6 14.3 0.1884 
  (2.7, 13.5)  (6.3, 28.2)  
      
Route/dose-form 13 13.8 0 0.0 0.0095 
  (8.1, 22.4)  (0.0, 10.0)  
      
Dose interval/timing 5 5.3 0 0.0 0.3235 
  (2.0, 12.2)  (0.0, 10.0)  
      
Duration 0 0.0 0 0.0 1.0 
  (0.0, 4.7)  (0.0, 10.0)  
      
Stop drug 
temporarily/permanently 
30 31.9       
(23.3, 41.9) 



















The distribution of the care issues within each of the subcategories in Check, Change 
in Drug Therapy Process and Change in Drug Therapy is included in table 16. The 
care issues found in Change in Drug Therapy are categorised as a Drug Therapy 
Problem. The results from the orthopaedic ward and cardiology ward are found in 
table 17.  
     










Unnecessary drug therapy 
 
27 (28.7) 16 (38.1) 
Need for additional drug therapy 
 
28(29.8) 3 (7.1) 
Ineffective drug 
 
9 (9.6) 1 (2.4) 
Dosage too low 
 
7 (7.4) 5 (11.9) 
Adverse drug reaction 
 
11 (11.7) 5 (11.9) 
Dosage too high 
 
4 (4.3) 4 (9.5) 
Inappropriate compliance 
 
7 (7.4) 8 (19.0) 
Unclassified 
 
1 (1.1) 0 (0) 
 
The total number of recommendations related to a change that the pharmacist made 
to the prescriber is presented in table 18. The distribution of the outcome of the 
recommendation is also found in the table.      
 







 n (% of total care issues) 
 
Total recommendations 171 (63.3) 80 (21.2) 
 n (% of total recommendations) 
Recommendations which remained a 
check 
 
15 (8.8) 9 (11.3) 
Recommendations which lead to a 
change in Drug Therapy Process 
 
67 (39.2) 37 (46.2) 
Recommendations which lead to a 







4.3 Focus group 
The focus group was held at the University of Strathclyde in Glasgow on the 28th of 
April 2008. All the persons invited attended, except for one (Table 19). The 
moderators gave a short introduction of the background for the project. Subsequently 
each section of the categorisation system were presented with the relevant results 
from the surveys that had been done in four different settings. During the 
presentation and for each part of the system the moderators asked questions that 
were made to identify the participants’ impression of the categorisation system 
regarding to comprehension and practical usability. New and changed parts of the 
system were especially in focus.    
 
The questions the moderators asked and the discussion among the participants that 
followed regarding these are presented in Table 20. One participant, GJ, arrived the 
about 40 minutes out in the focus group, when the part regarding recommendations 
and interactions. 
 
Table 19 Participants at the focus group 
 
Title Initials 
Clinical pharmacist, Ayr Hospital GJ 
Clinical pharmacist, Ayr Hospital KW 
Clinical pharmacist, Glasgow Royal Infirmary CF 
Clinical pharmacist, Glasgow Royal Infirmary LS 
Supervisor, Professor of Pharmaceutical Care,  









Table 20 Questions and themes with discussion at the focus group 
 
Question /discussed parts Discussion / opinions 
 
Any questions to the guideline?  
 
What your first impression of  
the guideline is? 
 
Is it readable?  
 
Is it possible to use the system by 
reading the guideline? 
 
- I think the concept of time perspective is a little bit unfocused. And I think the intention is that this has to do with a role 
in quality assurance and that the time perspective becomes a little bit secondary (SH). 
- I find it a bit complex, reading it. (LS) 
Two of the participants (LS and KW) commented that the parts of the system with checks and changes were easy 
understandable but that the Quality Assurance Descriptors were not system you could start using intuitively.  
The language used in the Quality Assurance System with classifications as ‘modifying’ and ‘adjusting’, or ‘confirming’ and 
‘verifying’ was mentioned to be difficult to differentiate and that this could affect the inter-rater reliability between the users 
of the system.  
 
Division of change 
We’ve tried to divide the changes 
category in two, and we would like to 
have your thoughts about a division like 
that. 
 
- In some ways I see the ‘health team member information/education’ as something outside the drug therapy process, 
rather then individual (…) patient related changes.(CF) 
The investigators explained that this category includes care issues related to ‘patient specific information on using 
medicines’.  
The participants would not necessarily refer to this type of issue as a change in drug therapy process, but that it rather is 
the drug therapy process and you more are assuming that it is a change. This part of the pharmacist’s work is not even 
always documented as a care issue in the care plan. The participants did agree on the following suggestion: 




Do you think the varying distribution of 
the subcategories between the wards 
can be explained or are they expected? 
 
The participants did agree on that the variations in ‘checks’ between the wards was as expected.  
- The expected compliance is quite high in care of the elderly, it is not really that surprising in all because… It depends on 
the type of ward(…) (LS) 
The high proportion of ‘medication need inquiry’ checks done at the orthopaedic ward was also mentioned to be explained 
by patient’s need for anticoagulation and proper analgesia. 
 
Change in Drug Therapy Process 
Can the differences and similarities you 
see here be explained and are they 
expected? 
 
- I think the clinical, sort of shared record, drug history, it probably so high on the Ayr side because the medical staff very 
much leaves that up the pharmacist, whether that’s right or wrong, to sort out the drug history and  to transcribe 
everything on admission so that probably makes the number pretty much as predicted(KW). 
A comment was made that the relatively low frequency of issues in ‘continuity of care’ at the cardiology ward could be due 
to under documenting in since these issues are done at the pharmacy and not at the ward. But it was cleared up that the 




Change in drug therapy 
The number of ‘Change in drug 
therapy’ was small for all wards and no 
care issues were put in the ‘Duration’ 
category at all. Do you think there is a 
need for this subcategory? 
Some of the participants were surprised of that this category was not used since you usually talk about ‘duration of 
therapy’. KJH explained how we had categorised everything about duration as stop drug or start drug. The duration was 
mentioned to either relate to switch to oral formulations or to change the duration as well, and that both of these would be a 
stop drug category.   
- I think there is an overlap here, and the definition potentially needs tidying up (CF). 
- So, duration is a change of the length of the course, that is more a subtle (SH) 
A suggestion was to split the ‘stop drug’ category into two, so that the duration is qualified within stop drug, as length of 
course necessarily can go on but no further comments were made on this. 
 
Drug therapy problems  
We wanted to discuss the need for the 
new eight category, ‘Unclassified i.e. 
Non-DTP’.  
 
Do you think it would be interesting to 
categorise care issues regarding cost 
savings for instance that will be 
unclassified other ways, because they 
aren’t clinical? 
 
Some of the participants reacted on that an additional category had been added to a standard categorisation system as the 
Drug therapy problems is. The issues should be tried to put in some of the existing categories.  
 
The participants agreed upon that the work pharmacists are doing regarding choice of non-formulary drug is an important 
part of their work and issues as such should therefore still be included in the categorisation system. However, there were 
some disagreement in whether these issues related to cost should be included to the category ‘ineffective drug’ or if it 
should be kept as an own category to be able to separate them out. 
 
- So if you are gonna have an extra category, call it something a little bit more specific (LS).  
Participants agree on this. 
 
Interactions 
This is not a part of the system today 
and is information we have gathered 
beside the system.  
Do you think interactions should be 
integrated into the system? 
 
General agreement among the participants that interactions in general are a just one among other checks that the 
pharmacist does to reveal if there is a need for changes in the patients drug therapy and that all these checks done not 
necessarily is written down routinely.   
- I think it’s the outcome, you’re saying dosage too high, dosage too low, it’s the outcome of the interaction.(GJ)   




As the interactions this part is not 
implemented in the system today. 
Do you think this information is 
interesting and that it should be 
implemented into the categorisation 
system?  
 
There were some confusion about what these results really showed and a comment was made on that the term 
recommendation was ill-defined. 
Some of the participants disagreed that these numbers should be characterised as ‘recommendations from pharmacist not 
acted upon’. This was one of the comments:  
- Usually when you may have identified something, a potential issue that you want to discuss with the prescriber, and you  
may think that a change is indicated, but on further discussion maybe further clinical issues have come out in the 
discussion and overall hopefully you get consensus (CF)  
One of the participants (LS) expressed that this data could be useful (…). 
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Sum up check and change part 
Just in general, do these categories 
describe the pharmaceutical care 
delivered? 
Are there any categories you would like 
to see or that are missing so far? 
 
The participants agreed on the comment that: 
- Obvious you would get documented problem, individual practice is various at the moment (SH).  
The participants did not come up with any concrete missing parts. Some opinions about this part of the system was 
mentioned:     
- I think you got the basis of a degree of describing a lot of the (…) pharmacist contributions to care. And I think it’s 
probably some room for some tweeking (CF)  
It was pointed out that these results revealed a problem caused by the electronic prescribing system in Ayr. 
A participant mentioned that the proportions of the workload could give ideas if it is a reasonable distribution. 
 
Time Perspective  
The results from the surveys about 
distribution within the ‘verification’, 
‘monitoring’ and ‘confirmation’ were 
presented. 
What does the ‘Time Perspective’ add 
to the description of the pharmaceutical 
care? 
How do you comprehend this category 
and the subcategories? 
 
There was obviously confusion among the participants while this part was presented and it was stated that categorising 
both checks and changes into the Time Perspective could make it even more complex and difficult for the participants to 
understand.    
- This is very, very far from the original system (…)(SH). 
A problem was that the terms used in this category seemed to mean the same thing for the participants. A redescription of 
the categories used was suggested:    
- (...) if you say it happen at the design stage or the delivery stage or the evaluation stage. (…) Then you avoid the 




Quality Assurance  
Degree of change 
The results in this category were 
presented.  
What does the Degree of Change add 
to the description of the pharmaceutical 
care? 
How do you comprehend this category 
and the subcategories? 
 
- I’m surprised there were not many reviews, generally.(SH) 
A explanation to that was suggested could be due to the short stays for the patients 
 
Clearly the terms used also here are more difficult to relate to for the participants. 
Many examples of changes in practice were referred to and suggestions of their placing in the category were discussed. 
One main problem mentioned was that the pharmacist usually don’t set treatment goals and that this can explain the low 
frequency of ‘reviews’.     
 
Summing up 
Which potential uses you can think of 
for this system all the categories we’ve 
presented today included?  
Can you mention anything positive and 
negative sides about the system? 
 
- You can prepare pharmacists, and pharmacist can benchmark their practice and see what they need to be working on. 
(..) It makes you thinking: it makes you thinking about process, it’s make you thinking about the patient actually going 
home and evaluating the outcome in another term. The negative is that’s quite complex.(LS) 
 
Participants did agree on the comment that: 
The more intuitive you can make it, the better  (LS) 
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4.4 Inter-rater reliability testing of the categorisation system 
The inter-rater reliability for categorising care issues found after the training period 
was analysed by using Cohen’s kappa statistic. The higher value of kappa the higher 
is the agreement between the two raters. There is no absolute definition for the 
interpretation of the kappa value but a scale for the different kappa values is shown 
in Table 21 as a guideline. The value of kappa from the tests done is given with a 95 
% confidence interval in the tables 22-25. The relative observed agreement (po) and 
the relative observed agreement (Pe) in each test are also included in the results. 
 
Table 21 Scale value of Cohen’s kappa(47) 
 








0.81-1.00 Highly good 
 
Table 22 Result of inter-rater agreement in the categories Check, Changes in Drug 
Therapy Process and Changes in Drug Therapy 
 
    
 
Investigator B  
   

















 Pe 0.41 
   Check 55 0 0 55 
   
   




0 17 0 17 
   
   
   
Change in 
Drug Therapy 
2 2 24 28 
   
Total 57 19 24 
 





Table 23 Result of inter-rater agreement within the subcategories of the Checks, Changes in Drug Therapy Process and Changes in Drug Therapy 
Investigator B  
Checks Changes in Drug Therapy Process Changes in Drug Therapy  
Investigator A MED EFF SAFE COMP CHAR DH CONT MON INF SEL DOSE FORM INT DUR STOP EDU Total 
MED 11 1   1                         13 
EFF 4 12                             16 
SAFE     24                           24 
Checks 
COMP       2                         2 
CHAR         1                       1 
DH           15                     15 
CONT             1                   1 





INF                 0               0 
SEL 1         1       8             10 
DOSE     1     1         4           6 
FORM                       0         0 




DUR                           0     0 
STOP                   1         9   10 
  
EDU                               1 1 
Total        16      13  25 3 1 17 1 0 0 9 4 0 1 0 9 1 100 
                   
κ 0.87 (0.46, 1.28)                
Strength of 
agreement Highly good                
Po 0.89                
Pe 0.85                
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Table 24 Result of inter-rater agreement in the categories verification, monitoring and confirmation  
 
Quality Assurance Descriptors: Time perspective 







 Po 0.87 
Investigator A Verification Monitoring Confirmation Total  Pe 0.46 
   
   Verification 44 1 0 45 
   
   
   Monitoring 7 42 4 53 
   
   
   Confirmation 0 1 1 2 
   
Total 51 44 5 100 
 
   
 
The results from the inter-rater agreement test of the quality assurance descriptors in 
‘Time perspective’; verification, monitoring and confirmation are presented in table 
24. A similar test done for the issues that were assigned a quality assurance 
descriptor within the ‘Degree of change’ (Table 25)      
 
Table 25 Result of inter-rater agreement in the categories adjustment, modification and review 
 
 
Quality Assurance Descriptors: Degree of change 
 





agreement Moderate  
Po 0,79 
Investigator A Adjustment Modification Review Total  Pe 0,63 
   
   Adjustment 16     2 0 18 
   
   
   Modification 3 2 0 5 
   
   
   Review 0 0 1 1 
   
Total 19 4 1 
 
24 





5.1 Known differences in the delivery of the service to the 
orthopaedic ward compared to the cardiology ward 
The main difference between the orthopaedic and the cardiology ward is found in the 
way the discharge process is organised. As the orthopaedic ward is a medicines re-
design ward including re-use of patient’s own drugs and one-stop dispensing 
schemes, the verification of the prescribed medicines to take away on discharge is 
done by the pharmacist on the ward. By doing this process on the ward the nurse 
and medical staff are easily available to clarify the patient’s need for the prescribed 
medicine and any other outstanding care issues. At the cardiology ward on the other 
hand, the discharge letter including prescribed medicines to take away is sent 
electronically from the doctor on the ward to the dispensary. There a pharmacist 
checks the prescription and consults with the doctor on the ward if needed before it is 
verified and the medicines given to the patient.  
 
This difference in the way the discharge process is organised obviously results in 
differences in what the pharmacist spends his/her time doing on the ward. At both 
wards most of the time spent is on the clarification of the drug history to the patient 
and follow-ups of active care issues. To reduce the work load for the pharmacist in 
relation to the discharge process in the medicines re-design ward the technicians are 
attending the ward every day. In addition to assessing the patient’s own drugs and 
preparing the medicines to take away on discharge they are giving the pharmacist 
assistance in the pharmaceutical care given. An example is when the pharmacy 
technician gives the patient their medicines on discharge with the information that is 
necessary.  
 
5.2 The care plan template draft 
The care plan template draft made by the investigator and co investigator ROH is 
supposed to optimise the pharmacist’s documentation of their contributions to the 
patient’s care (Figure 5). There are several reasons for having a care plan template. 
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Compared to a free text electronic record that is used at the Ayr Hospital at today, a 
care plan template will make the plan more structured and complete. A care plan 
template has also the advantages of making the pharmacists’ documentation process 
more effective and uniform between pharmacists. The care plan template is drafted 
by using care plan drafts from different settings as a starting point and including 
ideas generated during the survey and through a group meeting with the clinical 
pharmacists at the Ayr Hospital. An example from the survey of a patient free text 
electronic care plan is found in appendix 1 and is also made in the proposed patient 
template care plan found in appendix 2. 
 
The patient’s care plan is a document that is used by several people within the 
hospital during the hospital stay. For this reason a good care plan template should 
make it easy to get an overview of how the pharmaceutical care is intended to be 
provided and to document which actions that have been undertaken in this process. 
The aim by using the care plan template should be to capture as much as possible of 
the work done. By implementing the information from different forms and databases 
the pharmacists use, and often duplicates into the free text record today, the care 
plan will end up as a more complete document of the contribution in the 
pharmaceutical care. An example of the forms that should be implemented is the 
‘Medicine Reconciliation Form’ that is used in paper form today when taking the 
patients medication history. But also other parts of the system as laboratory results 
and information from the patient’s demographics, in the electronic prescribing system 
could be a part of the care plan template. This can reduce the time the pharmacist 
spend on duplicating information and also reduce the risk of error when transcribing 
into the care plan.   
 
One of the main advantages with an electronic documentation system is the 
possibility to audit trail all the actions made on it. The idea for this care plan template 
is to give each clinical pharmacist an individual profile within the electronic 
prescribing system and in that way all the contributions the pharmacist makes to the 
care plan is automatically signed with the name and date for the pharmacist. In this 
way no new information is added without knowing who did it. The pharmacist profile 
can also contain different help functions that the pharmacist can use during the work 
on the ward. This is thought to include calculations for example for eGFR, digoxin 
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levels, BMI from the weight and height etc. and the pharmacist can choose to switch 
these functions on or off according to what he/she wants. The pharmacist can ideally 
choose lab results that are relevant, and have these implemented into the 
investigations section in a similar manner as the weight is updated from the 
electronic prescribing system. These results could also then update themselves 
when a new sample is drawn and present values out of range. The care plan 
template is not meant to be a complex system of technical functions but a tool to help 
the pharmacist making their documentation easier.  
 
In the care plan template draft information as presenting complaints, past medical 
history and relevant drug history can be written in free text boxes in the care plan. 
When the pharmacist verifies the medicines in the electronic prescribing system and 
ticks the “Medicines on admission” box these will appear in this section of the care 
plan. The care plan template contains most of the already existing ‘Medicine 
Reconciliation Form’ used at the Ayr Hospital where among others drugs on 
admittance, OTC, herbals and etc. can be documented. All information on this form 
that should be presented as care issues is intentionally omitted. E.g. notes about the 
patient’s compliance, need for compliance aid, number to community pharmacy, if 
the patient is able to self administer drugs etc. The sources used for obtaining 
information for drug history can be ticked off in boxes for often used sources or be 
written in free text space for other sources. Only sources ticked of will later appear in 
the care plan. 
 
The care issue section is structured into three parts; the desired output of the 
pharmaceutical need, the action(s) planned to achieve the outputs and the actual 
output. Each issue’s review date outlines the priority of these. A function that sorts 
issues after review date could therefore make it easier for the pharmacist to get an 
overview of the care plan. The first coming review date would automatically be 
chosen as the care plan’s review date and will also appear on the top of the care 
plan. If the patient is not seen on the review date, the date will automatically be 
updated. Issues relevant for discharge can be marked by ticking the discharge box 
and be placed between the active and inactive care issues. The pharmacist writes in 
the number of days till review in the review date box, which converts it to the date for 
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review. The pharmacist is able to get an overview of each patient’s review date and 
the patients’ with no care plan started. 
 
Other technical functions the investigators has thought of as usable in the care plan 
template are for example a link from the prescribed orders in the electronic 
prescribing system to the care plan.  When the pharmacist withholds verification of a 
drug this can be automatically linked as an care issue in the care plan and so the 
pharmacist can go back there later and write the reason why. Each pharmacist can 
also make their own ‘shortcuts’ for making care issues. E.g. if a pharmacist has a 
patient with ST elevated myocardial infarction and writes the keyword *STEMI in the 
care issue field, there would be possible to choose a predefined text that the same 
pharmacist has added in as a function. In this way care issues that are typed several 
times a day can be pasted in automatically.  
 
A care plan template structured like this should not only facilitate the pharmacists 
daily work on the ward, but also make it possible to gather data and do research on 
the contribution the clinical pharmacist makes to the patient’s pharmaceutical care. 
With a more structured way of presenting the care issues these can be analysed, 




5.3 Comparison of the pharmaceutical care data from the survey at 
the orthopaedic ward and the cardiology ward  
5.3.1 Drug history on admission and sources used to obtain it at the 
orthopaedic and cardiology ward 
Looking at the number of drugs per patient on admission there were found to be no 
statistically difference for the orthopaedic ward and the cardiology ward (Table 13). 
This number includes medicines the patient was prescribed before admission to 
hospital. This includes not OTC, herbal medicine etc. The number of sources used to 
obtain the patients drug history is those that the pharmacist documents used in the 
care plan. At both the orthopaedic ward and the cardiology ward this information is 
most often obtained by using two different sources. Among 10% of the care plans at 
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the orthopaedic ward the information source used is not documented. The 
pharmacist documents the patient’s medicines on admission on the ‘Medicine 
Reconciliation Form’ which is filed in the patient’s notes. This documentation should 
also be duplicated in the free text care plan but is potentially forgotten. This 
documentation procedure in both the written medical notes and care plan is a time 
consuming activity for the pharmacist.  
 
In both settings the patient is the source of information most often used when the 
drug history to the patient is obtained (Table 13). The percentage use of the patient’s 
own drugs as a source of information is higher on the orthopaedic ward (27.4% of all 
sources) compared to the cardiology ward (11.4% of all sources) and can be 
explained by the difference in the use of the PODs while inpatient at the orthopaedic 
ward and not at the cardiology ward.  
 
5.3.2 Patient characteristics  
The statistical analysis of the patient characteristics shows that there is no 
demonstrable difference between the two wards in terms of age and number of 
diagnosis (Table 14). The number of diagnosis is obtained by the investigators 
through those noted in the patient’s care plan and also additional findings in medical 
notes. This can be incomplete since more often only relevant diagnosis is 
documented in the notes on admission. The length of stay has a mean (CI) of 9.0 
(7.5,10.5) days at the orthopaedic ward and 7.2 (5.5,8.9) days at the cardiology. The 
mean values are outside the 95% confidence interval which means that it is a 
difference between the length of stay to the patients at the two wards. The t-test 
gives a p-value of 0.16 and no statistically difference is therefore found. This 
difference in the statistical analysis can be due to that the patient population does not 
show normal distribution.  
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5.3.3 Pharmaceutical care activity at the orthopaedic ward and the cardiology 
ward 
 
The difference in the number of pharmaceutical care issues identified per patient in 
the two settings is statistically significant with a higher mean (CI) at the cardiology 
ward than at the orthopaedic ward (5.3 (4.2,6.5) versus 3.0 (2.6,3.4)) (Table 14). This 
can possibly be explained by the difference in the group of drugs the patients at the 
two wards use. The medicines on the cardiology ward can possibly generate more 
issues related to closely monitoring than the medicines that are found among the 
patients at the orthopaedic ward. Looking at the distribution of the care issue within 
the Check, Change in Drug Therapy Process and Change in Drug Therapy this 
difference is revealed through the number of Check done per patient. The number of 
Checks at the cardiology ward is found to give a mean of 3.8 for Check per patient 
while the value for the same category at the orthopaedic ward is 1.1, p<0.0001  
 
The Check category includes all the care issues related to when the pharmacist is 
doing a check to ensure that the patient’s treatment is safe and effective. The data in 
table 16 confirms that the Check for ‘Safety inquiry’ is higher on the cardiology ward 
compared to the orthopaedic. When adding the ‘Time perspective’ categories in 
Quality Assurance Descriptors to the checks, information is revealed about if the 
check was performed at the start of the treatment, during treatment or as a check for 
that the treatment was stopped. As seen in table 15 most of the checks for both 
wards are done during the patient treatment; as a monitoring check.  
 
The care issues that were not categorised were so because the outcome of the care 
issue was unknown. The data from the survey does not show any differences 
between the numbers of care issues not categorised per patient (table 14). The 
method used for the data gathering with an action research approach where the 
investigator regularly talks with the pharmacist should ensure that all actions taken, 
also those not documented in the care plan, have been captured. There are various 
reasons for why the care issue has not got any outcome. It can be due to that the 
patient is not seen by a pharmacist on discharge. This happens when the patient is 
discharged to another hospital ward. On this type of discharge no discharge letter 
with prescription is made and of this reason the patient does not necessarily get a 
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review by the pharmacist before discharge. Prescriptions for patients discharged on 
Sundays are not verified if not the day of discharge is planned in advance and 
therefore reviewed by a pharmacist before the weekend. All care issues where the 
treatment is to be reviewed by the pharmacist on discharge are therefore without an 
outcome and is not categorised. Other examples are situations where the drug in the 
care issue is discontinued before monitoring was done by the pharmacist and it does 
therefore not get any outcome.  
 
The occurrence of ‘Medication need inquiry’ within the category Checks (Table 16) is 
higher at the orthopaedic ward compared to the cardiology ward. Care issues found 
in this group are typically checks performed by the pharmacist to ensure that short 
term treatments as antibiotic courses, anti-emetics after operation and analgesics are 
either started or stopped during the hospital stay. A check done to ensure that the 
patient is started on DVT-prophylaxis after a major operation is also found in this 
category. This check will in the ‘Time perspective’ categories be related to as a 
verification check for the new treatment started.  The data in table 15 for ‘Time 
perspective’ reveals that while the orthopaedic ward has a relative high number of 
checks that are confirmations, while no confirmation checks were found in the care 
issues from the cardiology. These confirmation checks are typically checks to assure 
that expected effect of treatment are achieved. For example that an effective 
antibiotic treatment is stopped or that the patient does not suffer from pain any more 
and therefore have no need for analgesics. These results can possibly be related to 
that antibiotic prophylaxis courses are more common among the patients at the 
orthopaedic.  
 
From the results in subcategories within the ‘Change in drug therapy process’ the 
differences in ‘Clinical (shared ) record of patient characteristic’ and ‘Clinical (shared) 
record of drug history’ are commented below (Table 16). The cardiology has a higher 
prevalence of changes in ‘Clinical (shared ) record of patient characteristic’ compared 
to the orthopaedic ward where no such changes were found among the care issues 
identified (15.9% vs. 0%, p=0.0002). These changes are typically an up-date of the 
patient’s allergy status. It is interesting that it was not found any care issues in this 
category among the care issues generated from the orthopaedic ward. One possible 
reason for this can be that for all of the elective admissions to the orthopaedic ward 
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the assessment of the patient including allergy updates is done at the pre-
assessment clinic. Any up-dates done there will not be included as a care issue in 
this survey since all of it is performed outside the orthopaedic ward.  
 
The finding of changes categorised into the subcategory ‘Clinical (shared) record of 
drug history’ is relatively high in both wards but statistically significant higher at the 
orthopaedic ward compared to the cardiology ward (Table 16). The care issues in 
this category are related to changes made to drugs prescribed in error or missed out 
on admission. This result indicates that the pharmacist spend much of their time on 
the ward ensuring that the patients are prescribed all of their regular medicines with 
dosages and frequencies similar to what they usually are prescribed outside the 
hospital setting. It is worthy of note that for all the patients for elective admissions at 
the orthopaedic ward the drug history is taken by the pharmacist on the pre-
assessment clinic. This means that the total number of changes in the ‘Clinical 
(shared) record of drug history’ mainly relates to errors in the drug history taken for 
the emergency admissions and point out the need for a pharmacist taking drug 
history at the ward. 
 
Changes in both of the above mentioned subcategories in ‘Change in drug therapy 
process’ will be assigned a check for ‘verification’ in the ‘Time perspective’. Put 
together they can therefore explain the high portion at both wards of verifications in 
the ‘Change in drug therapy process’ category (Table 15).  
  
The results for the subcategories in ‘Change in Drug Therapy’ are presented in table 
16. For the cardiology ward the total number of care issues within this category is 
relatively small (n=42). The subcategory ‘Stop drug temporarily/permanently’ 
constitutes more than half of the changes in drug therapy at this ward. The high 
prevalence of stop of treatment seen here can partly be explained by a problem 
caused by the electronic prescribing system; when a drug is intended to be stopped it 
is often only ‘suspended’ by the doctors on the ward. This brings about many care 
issues where the pharmacist must ask the doctor to change the order from stop drug 
temporarily to stop drug permanently. 
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All the care issues categorised in ‘Change in drug therapy’ will also be categorised 
into a ‘Drug Therapy Problem’ (Table 17). The ‘Drug Therapy Problem’ category 
reveals more of the reason for the change in the patient’s therapy. Together these 
two categories fully describe what in the drug therapy that was changed and why it 
was changed. At the cardiology ward most of the ‘Drug Therapy Problems’ are found 
to be ‘Unnecessary drug therapy’ and most of the changes in drug therapy are 
therefore done due to this. For the orthopaedic ward most ‘Drug Therapy Problems’ 
are found to be ‘Need for additional drug therapy’. The numbers of care issues 
related to not patient specific changes due to non-adherence with local formularies 
was very low, only one care issue found at the orthopaedic ward and no such issues 
at the cardiology.  One explanation to these small numbers can be that the 
prescribers can choose medicines only included in the local formulary of the hospital 
when adding an order in the electronic prescribing system.  
 
For all the subcategories within ‘Change in drug therapy’, except for ‘Patient or Carer 
Level of Education (Understanding/Compliance)’, the pharmacist must make a 
recommendation to the patient’s prescriber, which must be carried out to make a 
change in the drug therapy. The distribution of these care issues within the ‘Time 
perspective’ category is found in table 15 and gives information about at which stage 
in the patient’s treatment cycle these recommendations were made. The ‘Changes in 
drug therapy’   from the two wards show a similar distribution within the ‘Time 
perspective’ category with most changes in ‘verification’ followed by ‘monitoring’ and 
’confirmation’. This can give a description of how the pharmacist works at the ward; 
most of the recommendations the pharmacist makes is done at the start of the 
treatment when he/she checks if the drug, dose, frequency, route of administration 
etc. and find that they are not appropriate or optimal for the patient. Further some 
changes are recommended during the treatment (for example if the patient’s 
condition changes) and some changes are recommended because the expected 
effect of the treatment are achieved.   
 
Only the care issues categorised as a Change in Drug Therapy (and ‘Drug Therapy 
Problem’) are also given a quality assurance descriptor within the ‘Degree of change’ 
(table 15). From the results most of the changes in the patients’ drug therapy were 
described as ‘adjustments’. These changes are made within the treatment plan to 
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individualise the treatment to the patient and can for example be a change of dose 
according to the patient’s weight or that aspirin prescribed to a patient with a history 
of gastrointestinal upset must be stopped. The results from the survey show that 
‘reviews‘ are seldom found among the changes (table 15). This can be explained by 
the relative short stays the patients have on the hospital where the patients 
presenting complaints are prioritised before a total re-assessment the patient’s 
treatment.  
 
Sometimes the change in the patient’s treatment is made by the prescriber after a 
recommendation from the pharmacist. Of the total number of care issues 63% of 
those identified at the orthopaedic (ward and 21% of those identified at the cardiology 
ward included a recommendation from the pharmacist (table 18). The cases where 
the pharmacist makes a recommendation to a change that the prescriber does not 
carry out is categorised as a check. This data is not a part of the system as it is today 
and was gathered beside the other part of the categorisation system. These numbers 
can be a measurement of the degree the pharmacist has an influence on the 
patient’s treatment.      
 
5.4 Focus group 
At the focus group consisting of clinical pharmacists, the projects academic 
supervisor and the investigators the modified version of the categorisation system for 
care issues was discussed. Results from the surveys the investigators had done 
were presented to give a better idea of how the system works in practice and to give 
a discussion around the modified parts of the categorisation system. 
 
The participants of the focus group agreed that the categorisation system is partly 
difficult to comprehend. The intention for a categorisation system is that it should be 
easy to understand and use by pharmacists, who are the target group for the system. 
A language which describes the different activities the pharmacist performs within the 
pharmaceutical care must therefore be developed and used in practice. Some of the 
terms as ‘verification’ and ‘confirmation’ used in the system today can be difficult to 
differentiate and because they are terms that already exist to describe activities on 
the ward it makes the categorisation harder to understand. One of the participants 
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suggested that instead of using these terms for the subcategories within the ‘Time 
perspective’ the related stage; design, delivery or evaluation to each check should be 
underlined.  
 
The division of the change category was one of the major changes that were done by 
the investigators during the modification process. Some of the participants of the 
focus group stated that actions found in the subcategory ‘Health team member 
information/education’ within the Change in Drug Therapy Process actually would be 
hard to characterise as a change in the process and that it rather was the drug 
therapy process. This comment emphasised the statement for the division of the 
change category that the investigators had from the start of, where the actions taken 
related to the process around the patient and the patient’s treatment results in 
outcomes that are hard to determine. Care issues related to patient specific 
information on using medicines that the pharmacist gives to other health team 
members are an important contribution to the pharmaceutical care for the patient. 
Since using the word change to describe these subcategories can be confusing the 
suggestion from the participants to exchange it with contribution and end up with 
‘Contribution to drug therapy process’ and ‘Change in drug therapy’, could make it 
clearer. 
 
During the focus group especially two subcategories in ‘Change in drug therapy’ and 
‘Drug therapy problem’ were discussed. In the results from the categorisation of the 
care issues generated from the survey the subcategory ‘Duration’ within ‘Change in 
drug therapy’ was not used once among any of the investigators. The need for this 
subcategory was therefore discussed on the focus group. No clear outcome of the 
question was obtained although it was suggested to include the duration as a part of 
the ‘Stop drug temporarily/permanently’’ category. The subcategory which the 
investigators had added to the Cipolle and Strands classification of Drug Therapy 
Problem was also discussed. This eighth category captures the issues related to cost 
effectiveness questions in the pharmaceutical care. It can be discussed whether this 
is a part of the drug therapy problems and it can be viewed in different ways related 
to it is a part of the ‘Ineffective drug’. However, it is a fact that cost related factors are 
important in the system and the pharmacist must take into consideration while 
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assessing the treatment of the patient. Therefore an own category for this type of 
care issues could be of valuable. 
    
During the survey the investigators gathered data regarding two aspects of the 
pharmaceutical activity that were not captured in the modified categorisation system.  
This was information about care issues related to drug interactions and notification of 
the cases where a pharmacist makes a recommendation to the prescriber which is 
either acted upon or not. The numbers found on drug interaction related care issues 
were very small. The participants’ comments to this part were that they saw this as 
one of other type of checks the pharmacist does all the time. The data regarding the 
pharmacist’s recommendation on care issues were presented and some reactions on 
the use of the term recommendation were mistaken. Some of the participants didn’t 
like the term ‘recommendations from pharmacist not acted upon’ that was used. 
When a potential issue is discovered in a clinical setting the pharmacist always starts 
a dialog with the prescriber and in the discussion which follows the two parts agree 
on something that may not were the pharmacist’s suggestion in the first part.        
 
Another part of the system that the moderators wanted to get feedback on was the 
Quality Assurance Descriptors. In the section with the ‘Time perspective’ it was 
commented that the way the categorisation system was changed to describe both 
Check and Change in the Time perspective it was very far from the original system. 
This was thought to make it even more complicated for the other users of the system. 
For the part of the system with the ‘Degree of change’ comments were made on that 
the number of reviews found were few. But the short stay for the patients was 
suggested as one reason for that another one could be that the pharmacists not 
usually have treatment plans and that the difficulties in knowing the goal for the 
treatment can lead to few reviews. The participants expressed difficulties in 
understanding the terms for this category as well.  
 
 
In the end of the focus group all the parts of the categorisation system were summed 
up and in which way the system can be useful in practice. It was mentioned that 
pharmacists can use it to benchmark their practice and see what they have to work 
more on. Other opinions about the system were that the check and change part 
make a basis where he pharmaceutical care can be described.       
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5.5 Inter-rater reliability testing of the categorisation system  
5.5.1 Inter-rater agreement within the Check, Change in Drug Therapy Process 
and Change in Drug Therapy 
The strength of the agreement between the investigators in categorising care issues 
in either the ‘Check’, ‘Change in Drug Therapy Process’  or ‘Change in Drug Therapy’ 
categories is found to be ‘highly good’ on the scale of kappa values (table 22). In the 
test presented in table 23, where the subcategories for the same three groups where 
included, the strength of the agreement between the investigators was reduced to 
some degree due to that more differences in the choice of subcategory were 
revealed. 
 
The investigator found this part of the categorisation system relative easy to use, but 
to get the same outcome between the raters it is necessarily important that the 
involved raters have understood the situation the care issue describes in the same 
way. If the situation described is quite complex or if the issue is not described specific 
enough it can lead to different assumptions of what actually happened in the 
situation. A care issue where the raters do not agree in whether it was a check or a 
change can for example appear when the pharmacist’s action in this issue is 
understood different between the raters. If the change is understood as a result of a 
recommendation from the pharmacist it is categorised as a change, but if the 
investigator that the pharmacist only checked for that the change had been done it 
would fall into one of the check categories.In a same manner a care issue describing 
a change can be categorised differently into change in process and therapy due to if 
the situation described was got as a drug history clarification or not. Is the situation 
understood as it describes an error prescribed on admission this will be categorised 
as a change in ‘Clinical (shared) record of drug history’  while if this is understood as 
a change made in the patients treatment during the stay this care issue will fall into 
one of the subcategories in Change in drug therapy.  
 
The inter-rater reliability test revealed that the investigators had some unclearness 
around if a care issue classifies as a check for medication need or effect. These 
issues where often related to monitoring of duration of supplements, where one of 
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the investigators regarded the check for duration of the treatment in different ways. 
While one understood it as the pharmacist were checking for if the supplements were 
to be given any longer the other investigator understood the situation as if the 
pharmacist wanted to confirm that the supplements had given effect.  
 
 
5.5.2 Inter-rater agreement in the categories verification, monitoring and 
confirmation 
The inter-rater reliability between the two investigators was tested for the ‘Time 
perspective’ of the Quality Assurance Descriptors (table 24). The overall agreement 
between the investigators for this group gave a kappa value κ = 0.76. The distribution 
of the disagreements among the raters shows that the difficulties in this part of the 
system lies in whether the care issue is a ‘verification’ or ‘monitoring’ and if it is a 
‘monitoring’ or ‘confirmation’. To be able to differentiate a verification from a 
monitoring the care issue must give the rater sufficient information whether this is the 
first time the pharmacist comes across the patient’s treatment or not. It is obvious 
that the care issue is a verification if the it tells that the check for example is done on 
admission. The monitoring is happening if the pharmacist’s action is done further out 
in the patient’s treatment course.  
 
5.5.3 Inter-rater agreement in the categories adjustment, modification and 
review 
The result of the inter-rater reliability test of the part of the system ‘Degree of 
Change’ resulted in the weakest agreement between the investigators (Table 25). 
The kappa value was estimated to be 0.44 which interprets as a ‘moderate’ 
agreement on the scale in table 21. The disagreements among the raters were found 
in the subcategories of ‘modification’ and ‘adjustment’.  
 
The subcategories in this part of the categorisation system shall describe the degree 
of change made in the patient’s treatment. To be able to evaluate how big the 
change is you have to know something about the expectations for the treatment of 
the patient. This set a focus on the need for a treatment plan for the patient’s 
condition. Since a treatment plan for the patient that includes a goal or desired 
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outcome in most cases is not known, it is more difficult to know how far the change 
differs from the expected course of the treatment. This was therefore the part of the 
system the investigator had to put most effort in to understand.   
 
Only care issues categorised as a Change in drug therapy is further categorised in 
the Quality Assurance Descriptors ‘adjustment’, ‘modification’ and ‘review’. 
Therefore, if the care issue is to be assigned to one of the categories within the 
Degree of Change it depends on where it is found in the check and change part of 
the system. This means that for all situations where one investigator categorise the 
care issue within the Change in drug therapy while the other investigator assign it to 
one of the categories Check or Change in drug therapy process, only the former care 
issue will be assigned a Degree of Change category. As a consequence of this 
disagreement these care issues can not be included in the inter-rater test of this last 
part of the system. Four of the care issues in the random sample for the inter-rater 
reliability test were categorised different between the raters as explained above and 
were therefore excluded from this test.  
 
5.6 The future of a categorisation system for care issues  
There is need for a categorisation system that can be used to describe the 
pharmaceutical work that is performed around in different care settings. To make it 
useful it is important that it describes all parts of the contributions a pharmacist make 
to the pharmaceutical care but that it at the same time not get too complex and 
difficult to understand. 
 
The most difficult part with the categorisation system as it is today is the description 
of where the pharmacist is involved in the patient’s treatment and to what extent this 
changes the patient’s treatment. The section with the Degree of Change in the 
Quality Assurance Descriptors is a way of describing the changes in the patient’s 
drug regimen that is not easy applicable in practice because of the lack of the same 
language. Both the comments from the focus group participants and the result from 
the inter-rater reliability test confirm this. However, it is a good starting point to use to 
characterise parts of the health care system. In the further development of the 
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system one of the most important actions that must be started on is to develop a 
language that clearly defines the activities that it is desirable to include in a system.   
These descriptions must be transferable to all clinical settings. Secondly, the 
pharmacists must learn the way of thinking of the patient’s drug treatment as a 
cyclical process and the language describing it. If this is done the focus on having 
defined goals included in a treatment plan for the patients’ disease may be 
increased.   
          
 











Pharmaceutical care planning is well developed and has become a standard part of 
the pharmacist work in clinical settings in Scotland. The electronic recorded care 
plans that are made at the Ayr Hospital has the advantage compared to paper based 
care plans that they are more easily accessible and therefore facilitates the continuity 
between the pharmaceutical services within the hospital. However, there is a need to 
make the care issue documentation more complete and a care plan template where 
the pharmacist writes the care issues in a more structured way can make this 
possible.  
 
The development of a care plan template within an electronic system can open up for 
implementation of other databases or document with relevant information for the 
pharmacists. Together with other functions this can make the care plan template to a 
complete documentation of the pharmaceutical care provided. Potentially this can act 
as a pharmaceutical care profile for the patient that follows the patient when he or 
she is transferred between different clinical settings. The challenge is to make these 
ideas become a reality. 
 
The categorisation system as it is today is able to give data that describes which 
parts of the pharmaceutical care the clinical pharmacist makes a contribution to the 
patient’s treatment. The results from the survey found differences between the two 
clinical settings evaluated in where the pharmacist spends their time delivering 
pharmaceutical care. The differences can among other things be explained by the 
diagnosis and treatment within the patient population. The survey results also 
visualised a problem caused by the electronic prescribing system.  
 
The evaluation of the categorisation system found the system useful for pharmacists 
to benchmark their practice and in describing the activity of the pharmacist. It is a 
need for improving the language which describes all of the activities the pharmacist 
performs within the pharmaceutical care. By evolving the terms used in the Quality 
Assurance Descriptors these together with the check and changes can act as a 
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Appendix 1. Example of a patient free text electronic care plan and 
prescribed medicines in the electronic prescribing system 
Care plan 
PC:  Red, hot, swollen R ring finger (Excision boney swelling 4/52 ago)  Had flucloxacillin from GP 
 
PMH:  Prev excision boney swelling R thumb Aug 07, IHD, PCI, OA 
 
Meds:  From PODs and confirmed with patient 
 
Allergy:  Morphine - breathlessness, sweats, shivery (pt described 100 patch changed every 3 days - sounds more 
like fentanyl) 
Augmentin - D&V (OK with penicillin) 
 
Bloods: 
16/2  CRP 14, Hb 12.6, WCC 9.4, Pl 282, ESR 19  Pharm1 18/2 
17/2  Ur 5.4, Cr 76, K 3.7  Pharm1 18/2 
 
Issues: 
*1.  IV antibiotics - monitor route, duration and inflam markers  Pharm1 18/2 
 
*2.  Analgesia.  Admitted on DHC Continus 120mg bd and 60mg lunch.  GP is aware above max daily dose.  
For OA hip.  Advised to discuss with GP regular paracetamol and could perhaps cut out lunch dose DHC Cont.  
Annotate Discharge please.  Pharm1 18/2 
 
 




Appendix 2. Example of a patient template care plan 
 
PHARMACEUTICAL CARE PLAN 




    
 Female, 65  
    
 
Presenting Complaints  
Red, hot, swollen R ring finger (Excision boney swelling 4 weeks ago)   
 
P1, 18/2  
    
 
Past Medical History  
Prev excision boney swelling R thumb Aug 07, IHD, PCI, OA 
 
P1, 18/2  
    
 
Relevant Drug History  
Had flucloxacillin from GP 4 weeks ago P1, 18/2  










specify if not oral 
Dose Frequency Sign 
 
 Isosorbide mononitrate   MR tablet 60mg od  
 Nicorandil   10mg bd  
 Propanolol  40mg tid  
 Ramipril    5mg od  
 Simvastatin    20mg od  
 Clopidogrel  75mg od  
 Glyceryl trinitrate   Sublingual spray 400mcg prn  
 Dihydrocodeine MR 60 mg od  
 Dihydrocodeine MR 120 mg bd  
 Mirtazapine  Orodispersible tablets 45mg od  
 Mebeverine   135mg tid  
 Lormetazepam  500mcg od  
 Fybogel orange  Granules in sachets  od  
 Ranitidine   150mg bd  





OTC / Herbal / Homeopathic / Illicit substances 
 
 
 Add data   
       

















Morphine Breathlessness, sweats, shivery (pt described 




     
     
 Drug History  Sign  
   Patient   PODs P1,18/2  




Add data  
  
 Laboratory Results  
  
 Date Date Date Date Date Date 
 
 Test Range Units 16/2 17/2      
 CRP  < 5  mg/L 14       
 Hb  11.5-16.5 g/dl 12.6       
 WCC  4 -11.5 x109  l-1 9.4       
 Pl  150-400 x 109 l-1 282       
 ESR   1-9  mm/hr 19       
 Ur  2.5-7.5 mmol/l  5.4      
 Cr  50-80 mmol/l  76      
 K 3.5-5.0 mmol/l  3.7        
          
 
 
Pharmaceutical Care Issues  
         
 
  Active 




Analgesia.  Admitted on 
dihydrocodeine 120mg bd 
and 60mg lunch Ensure 
optimal analgesic treatment 







tablets qid prn  
Verificarion withhold by 
pharmacist 
[data from the EPS] P1,18/2 







Advised pt to take regular 
paracetamol and could 
perhaps cut out lunch dose 
dihydrocodeine P1,18/2 







 P1,18/2 Annotate discharge please  
 
Discharge  
         
 
  Active 






Monitor route, duration and 








markers   P1,18/2 
CRP and ESR out of 
range    
         
 
  Active 





Citalopram prescribed in 






Citalopram 10mg od 
Verification withhold by 
pharmacist 





         
 
Comments:  
• Laboratory tests is automatically updated and will be marked if out of range  
• Review dates are not always given in the free text record. In the template the pharmacist will be 
reminded to choose number of days till a review should be done. 
• The drug, dose and frequency will appear automatically in the action box when the pharmacist 
withholds the verifications of the drug in the electronic prescribing system    
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Centre Number: TAH 
Study Number:  




The study of Pharmacists Patient Records within the Ayr Hospital 
 
Name of Researcher:   
 
                   Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 
 January 2008 (version 1) for the above study. I have had the opportunity 
  to consider the information, ask questions and have had these answered 
 satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
 at any time, without giving any reason, without any medical care or legal  
 rights being affected. 
 
3. I understand that relevant sections of any of my medical notes and data  
 collected during the study, may be looked at by responsible individuals  
 from Ayr Hospital pharmacy department. I give permission for these 
    individuals to have access to my records.  
 
 




________________________ ________________ ___________________ 




_________________________ ________________ ___________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ___________________ 
Researcher Date  Signature 
 
 
When completed,  1 for patient;  1 for researcher site file;  1 (original) to be kept in medical notes. 
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Appendix 4. Patient paper profile used in the data gathering 
 
PATIENT PAPER PROFILE 
 
PATIENT DETAILS   
Number  Sex  Age  
Height N/A Weight N/A BMI N/A Ability to self medicate 
Allergies/Sensitivities  Type of reaction  
NKDA  
Social History  
 
 
PATIENT STAY Presenting Complaints Notes 
Admitted/Transferred from       
Date of admission to ward         
Discharge Date(Planned)          
Discharge Date (actual)            
Discharged to  
  
 
RELEVANT MEDICAL HISTORY RELEVANT DRUG HISTORY 
Date Problem Description Date Medication Comments 
     
 





RELEVANT NON DRUG TREATMENT  
Treatment Description Comments 
  
 
CLINCIAL MANAGEMENT  















       
       
 
 
REVIEWS        
Review Dates 
(Planned) 
         
Review Dates 
(Actual) 
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Appendix 5. The existing guideline used at the University of 
Strathclyde 
 
PHARMACEUTICAL CARE ISSUE DEFINITIONS 
 
Definitions of categories for recommended or implemented changes 
 
Adjust  - Adjustment is a change to the implementation of the treatment plan to 
individualise or optimise prescribing/administration/concordance. Adjustments occur 
as a result of monitoring actions. 
 
Review - a prompted review leads to a medical review of the patient’s treatment and 
their needs (due to inadequate response/unwanted drug effect/ change in a patient’s 
needs). 
 
Modify A modification is any change to the implementation of the treatment plan 
which is not an adjustment or review (including response to errors in 




Definitions of categories for recommended or implemented checks 
 
Verify - a verification is a check to exclude an initial error in prescribing/conditions of 
administration. 
 
Confirm - a confirmation is a written record of a patient/laboratory check that 
confirms medication has met expectations (in terms of defined goals for a given 
stage of treatment). 
 
Monitor - monitoring  is a periodic patient/laboratory check to ensure satisfactory 
implementation of the treatment plan and that further adjustment is not required. 
 
Normally a single care issue would address a single drug therapy problem (DTP). In 
the case of a care issue seeming to address more than one DTP, then the care issue 
may best be resolved into multiple care issues. There are two exceptions to this that 
we are prepared to recognise as common examples 
1. Checks of Dosage (Verification or Monitoring)  to exclude both too high and 
too low a dose will need to have three DTP categories (DTP4, DTP5 and 
therefore DTP6). This can only be avoided by recognising such checks as TWO 
care issues; a check for safety of the dose (and therefore DTP 5 + DTP 6) and a 
check for effectiveness of the dose (DTP 4) 
 
2. Checks for dose-related unwanted drug effects (Monitoring) will need to have 
two DTP categories (DTP5 and DTP6). This dual designation will carry an 
advantage in allowing the number of dose related ADRS (classed as DTP5 + 
DTP6) to be differentiated from non dose-related (DTP5 only). 
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3. Drug history checks are classified as addressing the prevention of Non-
Compliance (DTP7) to acknowledge the fundamental purpose and so avoid many 
and various other inconsistent interpretations. The DTP code DTP7 is also used 
when a change is made that communicates the discontinuation of a drug during 
transfer of care. 
 
4. Where checks of dosage involve initial check (verification) of dose and 
further check (monitoring), for instance of plasma concentration or clinical 
effect, then the separation of the designation of the actions requires the 
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Pharmaceutical care is delivered by a team of health care professionals. The focus of 
the categorisation system described here is pharmaceutical care contributions made 
by the pharmacist within that context.  
 
To better comprehend this guideline it is important to have an understanding of how 
the pharmacist provides pharmaceutical care. This is a cyclical process and will 
briefly be described here. 
 
The pharmacist initiates this process by gathering relevant information about the 
patient’s drug treatment and medical history, which reveals pharmaceutical care 
issues. The pharmacist handles the care issues by doing checks leading to three 
different results:  
 
1. The care issue is found not to be an actual or potential drug therapy problem 
that needs further follow up at this point. 
 




3. A drug therapy problem is identified and there is a need for a change in the 
patient’s drug therapy at this point  
 
 
2 Definition of a pharmaceutical care issue 
 
A pharmaceutical care issue is an identified concern regarding a potential or actual 
drug therapy problem. A drug therapy problem is patient specific, and so does not 
include non-adherence to local formulary choices that are based on cost controls. 
 
3 The categorisation system – a short summary 
 
The categorisation system is developed to describe pharmaceutical care. This is 
done by analysing each care issue and assigning them into categories. This 
categorisation process provides a basis for quantitative description of the 
pharmacist’s contribution to pharmaceutical care, which makes it possible to 
compare pharmaceutical care provided by a pharmacy service across different 
settings. 
 
Each care issue is described according to a triangularised system which consists of 
multiple categories. The advantage of combining different categorisation systems into 
one triangularised system is that the categories supplement and support each other, 
and therefore they capture the different dimensions of the pharmaceutical care 
issues.  
Each care issue is categorised in three such dimensions; 
(1) As either a Check or a Change1; where a Change may be a Change in the Drug 
Therapy Process or a Change in Drug Therapy, depending on the outcome.  
 
The care issue is further categorised into 
 
(2) Quality Assurance (QA) Descriptors1, which indicate a care issue’s position in the 
process of delivering pharmaceutical care. If the care issue is a Change in Drug 
Therapy this category also describes the extent of the change made.  
 
The third dimension in the system is  
(3) Drug Therapy Problem2 and only a care issue identified as a Change in Drug 
Therapy will be categorised as such. 
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If the outcome of the care issue is unknown, the care issue is incomplete and can not 
be categorised in the categorisation system.   
 
 
Table 1. Categorisation set-up 
Quality Assurance 
Descriptors 












       
 
The different parts of the triangularised system with its categories are described 
below. 
 
4 ‘Check’ and ‘Change’ categories 
 
4.1 Checks  
 
When a care issue is identified, the pharmacist has to perform checks in order to 
detect required actions to prevent future drug therapy problems or required changes 
in drug therapy addressing actual drug therapy problems. If the check leads to 
neither an action nor a change the care issue is categorised as a Check. A care 
issue categorised as a Check is assigned to one of four subcategories; “medication 
needs”, “effectiveness”, “safety” or “compliance”, based on the reason for the inquiry 
as summarised in table 2.  
 
The pharmacist’s intentions behind making the check constitute the basis for the 
number of care issues identified and for the categorisation of the identified check(s). 
A check performed by a pharmacist may be an inquiry which addresses both 
effectiveness and safety, (for instance when INR or lying/standing blood pressure is 
measured). In that case the care issue will be divided into two care issues; one check 
of effectiveness and one check of safety.  
If the pharmacist recommends making a change in the patient’s drug therapy in order 
to resolve or prevent a drug therapy problem, but the responsible prescriber either 
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doesn’t agree with the change or agrees but forgets to make it, the care issue will be 
categorised as a check because no change in the patient drug therapy is carried out. 
 






The category Change is divided into two types of subcategories; Change in Drug 
Therapy Process and Change in Drug Therapy. The Change in Drug Therapy 
Process category includes care issues relating to changes in the care process, and 
this means that the impact of the outcome often is hard to determine or is too 
speculative to lead to a Drug Therapy Problem category. The Change in Drug 
Therapy category, on the contrary, includes changes related to drug therapy, non-
compliance and prescription, where the outcome can be assigned a recognisable 
Drug Therapy Problem category. 
 
Even though all changes are inevitably the result of a check, such checks will not be 
categorised since their relevance is superseded by the resulting change. The care 
issue will be adequately described by the resulting categories of Change, Quality 
Assurance Descriptors and Drug Therapy Problem. 
 
5 Change in Drug Therapy Process 
 
The pharmacist performs different actions to address the pharmaceutical care needs 
of the patient. Not all of these actions result in a change to the patient’s drug therapy. 
Nevertheless it is important that these actions are quantified, as they comprise a 
great part of the pharmacist’s delivery of pharmaceutical care.  
 
Check Code 
Medication need inquiry MED 
Effectiveness inquiry EFF 
Safety inquiry SAFE 
Compliance inquiry COMP 
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The category Change in Drug Therapy Process describes the actions the pharmacist 
performs to prevent potential drug therapy problems and to identify actual drug 
therapy problems (Table 3).  
 
Table 3 Change in Drug Therapy Process categories 
Changes made to Code 
Clinical (shared) record of patient characteristics CHAR 
Clinical (shared) record of drug history DH 
Continuity of information/care between clinical settings CONT 
Level of patient monitoring MON 
Health care team member(s) information/education  INF 
 
 
5.1 Explanations of the Change in Drug Therapy Process subcategories 
 
Clinical (shared) record of patient characteristics  
This and the next subcategory describe actions that may affect the patient’s drug 
therapy since his/her treatment is based on available patient information. For 
instance, it is important to note in the patient’s record if he/she is allergic to 
penicillins, in case an antibiotic treatment is required later.  These actions help to 
avoid potentially preventable drug therapy problems in the future.  
 
If the pharmacist corrects or up-dates the patient’s shared records, for instance adds 
two drugs that the patient is allergic to, this will be recognised as one care issue. If 
drug therapy changes have to be made as a result of the corrected or up-dated 
record, this is recognised as one care issue for each drug that is changed.  
 
Clinical (shared) record of drug history  
When the pharmacist takes the drug history, discovers errors in prescribing on 
admission and proposes/makes a change to the drug therapy based on this, this is 
interpreted as one pharmaceutical care issue for each drug that is changed.  
 
Continuity of information/care between clinical settings 
This subcategory encompasses the actions the pharmacist undertakes to ensure 
continuity of care and transfer of relevant information between clinical settings, 
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including making new arrangements for the patient with other health care institutions.  
The clinical settings include all healthcare institutions that have responsibility for the 
patient’s health care.  
 
 
A number of care issues might be included globally in a document transferring the 
patient’s care between clinical settings. If the pharmacist prepares or advises on the 
document, but doesn’t follow-up on the recommendations made, that would be a 
single care issue. This is because the care issues have unknown outcomes, and 
therefore can’t be categorised. We can only categorise the action of the pharmacist 
in terms of making the recommendation. 
 
Level of patient monitoring 
Some care issues can result in the identification of a need to increase/improve 
patient monitoring.  This increased/improved patient monitoring doesn’t have to be 
performed by the pharmacist, but he/she must initiate it or advice about it. 
 
Health care team member(s) education / information 
This subcategory describes care issues where the pharmacist contributes by 
providing information or education to other health care personnel regarding the 
patient’s drug therapy. 
 
 
6 Change in Drug Therapy 
 
A care issue that is categorised as a Change in Drug Therapy (Table 4) includes 
changes to;  
• the drug therapy of the patient 
• the patient/patient’s carer understanding of the drug therapy or disease  
• the patient’s adherence to their treatment plan, that is patient compliance   
 
 
Pharmacists, unless they are acting as prescribers themselves, will in most cases 
make a recommendation to the patient’s prescriber, and the care issue will be 
categorised as a Change in Drug Therapy if the recommendation is accepted and 
carried out.  
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The outcome of changes made to the patient/carer understanding/compliance is hard 
to measure, but it is included in the Change in Drug Therapy subcategory because it 
can be categorised as a Drug Therapy Problem, and it can be viewed as a 
categorisation of the intention of the effort made by the pharmacist. 
 
 




7 Drug Therapy Problems (DTP)  
 
The categories of Drug Therapy Problems are those defined in the book 
Pharmaceutical Care Practice – The Clinician’s Guide 2 by Cipolle et al. The 
categories are given examples here to include a broader range of care issues. In 
addition they are modified to enhance the correlation between the heading of the 
DTP subcategories and the type of care issues included in them. An additional 
subcategory Unclassified has been added in order to categorise care issues where 
the change is not patient specific. For instance due to non-adherence with local 
formularies and with only cost-control implications, rather than medication safety or 
effectiveness. 
 
Only Change in Drug Therapy types of care issue will be categorised into Drug 
Therapy Problem categories. The combination of the Change in Drug Therapy 
subcategory and the Drug Therapy Problem subcategory will describe the nature of 
the change made to the patient’s drug therapy, see table 5 below. 
 
 
Changes made to: Code 
Drug selection (starting new or changing drug) SEL 
Dose  DOSE 
Route/dose form FORM 
Dose interval/timing INT 
Duration DUR 
Stop drug temporarily/permanently STOP 
Patient or Carer Level of Education (Understanding/Compliance) EDU 
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Table 5. Categories and common causes of drug therapy problems 
Drug Therapy Problem        Common causes of drug therapy problems 
 

















There is no valid medical indication for the drug therapy at this time 
 
Multiple drug products are being used for a condition that requires 
fewer drug therapies 
 
The medical condition is more appropriately treated with non drug 
therapy 
 
Drug therapy is being taken to treat an avoidable adverse reaction 
associated with another medication 
 
Drug abuse, alcohol use, or smoking is causing the problem 
 
The duration of therapy is too long 
 











A medical condition requires the initiation of drug therapy 
 
Preventive drug therapy is required to reduce the risk of developing 
a new condition 
 
A medical condition requires additional pharmacotherapy to attain 
synergistic or additive effects 
 
The duration of drug therapy is too short to produce the desired 
response 
 












The drug is not the most effective for the medical problem 
 
The medical condition is refractory to the drug product 
 
The dosage form of the drug product is inappropriate 
 
The drug product is not an effective product for the indication being 
treated 
 
The time of dosing or dosing interval is not the most effective 
 
Route of administration is not the most effective 
 







The dose is too low to produce the desired response 
 
The dosage interval is too infrequent to produce the desired 
response 
 
A drug-drug/food/lab/disease interaction reduces the amount of 





Table 5 (cont.) Categories and common causes of drug therapy problems 



















The drug product causes an undesirable reaction that is not dose-
related 
 
A safer drug product is required due to risk factors 
 
A pharmacodynamic drug-drug/food/lab/disease interaction causes 
an undesirable reaction that is not dose-related  
 
The dosage regimen was changed too rapidly 
 
The drug product causes an allergic reaction 
 
The drug product is contraindicated due to risk factors 
 
The time of dosing or the dosing interval is not the safest. 
 
Route of administration is not the safest 
 









Dose is too high 
 
The dosing frequency is too short 
 
A drug-drug/food/lab/disease interaction occurs resulting in a toxic 
reaction to the drug product 
 


















The patient prefers not to take the medication 
 
The patient does not understand the instructions 
 
The patient forgets to take the medication 
 
The drug product is too expensive for the patient 
 
The patient cannot swallow or self-administer the drug product 
appropriately 
 
The drug product is not available for the patient 
 














8 Quality Assurance Descriptors 
 
A patient’s drug treatment can be regarded as a cyclical process, which 
encompasses the design, delivery and evaluation of the treatment plan according to 
expectations predefined by clinical standards. Figure 1 shows the pharmacist’s 
systematic role as a contribution to increase the quality of this cyclical process. At 
each step during the cycle the pharmacist (and other health care team members) is 
in a position to perform checks to confirm the quality of the delivery of the treatment 
plan. Whenever the checks reveal deviations from the expectations established in the 
plan, changes to the treatment or the treatment plan are proposed or executed. This 
process can be viewed as a feedback loop, where changes are integrated into the 
cycle.  














Figure 1 Pharmaceutical care model  
 
The Quality Assurance (QA) Descriptors identify both the points in the feedback loop 
at which the care issues (the Checks or Changes) are implemented and the extent of 
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changes in drug therapy. To emphasise what they describe, the subcategories for 
QA Descriptors are designated Time Perspective and Degree of Change. 
 
All care issues will be categorised according to the QA Descriptor Time Perspective. 
This QA Descriptor adds a time perspective in the treatment cycle to the 
triangularised system. If the care issue is a Change in Drug Therapy it will be 
categorised according to the QA Descriptor Degree of Change as well. This QA 
Descriptor describes the extent of the change made (Table 6).  
 
Table 6. Summary of which care issues are categorised into the two different 
Quality Assurance Descriptors subcategories 
Quality Assurance Descriptors 
Time Perspective Degree of Change 
 
Check 
Change in Drug Therapy Process 
Change in Drug Therapy 
 
Change in Drug Therapy 
 
 
8.1 Time Perspective 
 
The subcategories of Time Perspective are Verification, Monitoring and 
Confirmation, see table 7.  These subcategories relate to the point in the system 
feedback loop where the initial check that identified the care issue was made. 
 
Table 7. Categorisation of checks according to quality system feedback loop 






medications in the 




Checks at the start of the treatment to make sure that, for 
each medicine, the patient: 
- is on the right medicine 
- is on the right dose 
- is not on unnecessary medication 
- doesn’t have any new needs for additional medication 
- is not receiving a combination of interacting medicines 
- understands how to take their medication and what it will 






treatment is appropriate 






Checks as treatment continues which should ensure that, 
for each medicine, the patient: 
- is on receiving medication as intended 
- continues to be on the most suitable dose 
- has no symptoms of unwanted(adverse) effects 




Checking that medication 






Confirmation and documentation to identify that 
medication is: 
- resulting in expected effects on the patient's condition 
- not failing to control condition 
- not producing unwanted effects requiring clinical review. 
 
Verification  
A ‘Verification’ is either done at the start of a new patient treatment or when the 
pharmacist first assesses the patient and the medication, see table 7. 
 
• In chronic disease management, for instance by a clinical pharmacist at an 
outpatient clinic or a community pharmacy, ‘Verification’ is done at the first 
episode of care with the pharmacist. That may or may not be at the start of the 
patient’s treatment but must be undertaken for the pharmacist to assure himself 
or herself that the proposed treatment plan is suitable for the patient’s need.  
 
• When the patient is seen in an interim episode of care interrupting chronic 
disease management, for instance by a clinical pharmacist at a hospital ward 
during an acute admission, the verification category will relate to when the 
pharmacist first saw the patient. ‘Verification’ of the patient’s drug treatment is 
done at admission, or when a new drug is started. All checks at this point in care 
should be categorised as ‘Verification’ even if the treatment has been going on for 




‘Monitoring’ is done during the patient’s treatment (during the delivery of the 
treatment plan) with the goal of assuring the medication process is being 
implemented as intended and within general expectations of signs of benefits 
and absence of adverse effects, see table 7. 
 
Confirmation  
‘Confirmation’ is an evaluation of the patient’s treatment to assure that expected 
effects are achieved, adverse effects avoided or suitably managed and that the 
condition is treated optimally, see table 7. This category usually applies to care 
issues concerning the continuing evaluation of a chronic disease, an acute 
exacerbation of a chronic disease, or an acute episode of disease 
 
8.2 Degree of Change 
 
The Degrees of Changes are Adjustment, Modification and Prompt a Review, see 
table 8. These three subcategories describe the extent of the change made. Both 
Adjustment and Modification may take place at the start or during treatment, while 
Prompting of a Review results from a failure in treatment and so only occurs after a 
trial period of treatment, see figure 1. 
 
Since it is difficult to distinguish between the extents of changes made in Change in 
Drug Therapy Process, only Change in Drug Therapy will be categorised into Degree 
of Change.  
 
Table 8. Categories of changes according to the extent of the change in the quality 
system feedback loop 
 
Degree of Change Code 
Adjustment ADJ 
Modification MOD 
Review (prompt a review) REV 
 
If a Check leads to a Change, the Time Perspective (i.e. at what time in the treatment 
cycle the check is done) will influence the choice of the subsequent Degree of 
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Change. As seen in figure 1 and table 9, a Verification can lead to either an 
Adjustment or a Modification. A Monitoring issue can only lead to an Adjustment. 
If a need for a bigger change in the treatment is identified, a Confirmation of the 
whole treatment of the patient is needed before a decision to either ‘modify’ or 
‘review’ the treatment can be made. A Confirmation can lead to either a 
Modification or a Review, depending on the outcome of the ‘confirmation’. 
 
Table 9. Categories of changes according to the time aspect in the quality system 
feedback loop, linked to preceding check 
 
Time Perspective Code Degree of Associated Change 
Verification VER ADJ MOD 






Adjustment is defined as a recommended change to patient behaviour, treatment 
regimen or process of continuity of care that individualises pharmaceutical care 
within the agreed treatment plan. ‘Adjustments’ are anticipated within the 
protocol/clinical management plan, and the regimen is not markedly changed to an 
alternative treatment regimen. Most supplementary prescribing decisions made by 
pharmacists would probably fall into this category. 
 
Modification 
Modification is a change to the patient treatment that is not anticipated and leads to 
a change of the patient’s treatment plan.  
 
Prompt a Review    
A Review is a re-assessment of the patient’s treatment, and leads to a change in the 
expectations defined by clinical standards i.e. change in the expectations to the 
outcome of the treatment. Because the pharmacist is not able to review the treatment 
alone, but has to recommend a review to the patient’s main prescriber, the qualified 
term category is termed ‘Prompt a Review’. ‘Prompt a Review’ is done as a part of 
the evaluation of the patient’s treatment. This will be done more often in an outpatient 
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